 


Joshua Levine | Professional Profile
 


























 









LinkedIn



















































Main content starts below.




Joshua LevineLocationGreater Los Angeles AreaIndustryMarketing and AdvertisingRecommendations6 people have recommended Joshua500+ connectionsView Joshua‚Äôs full profile. It's¬†free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View Joshua‚Äôs Full ProfileJoshua‚Äôs ActivityA First Look At Steven Spielberg‚Äôs Ready Player One
https...Joshua likedPhotoJoshua liked'Uber for trucking' startup, Transfix, raises $42M Series C...Joshua likedMy #Shabbat article for Inc.com, feel free to share,......Joshua likedWhy I'm so Lucky to be FiredJoshua likedSimple formula for living.Joshua likedSee all activitySkillsBudgetsCustomer AcquisitionMarketing StrategyForecastingMergersStrategic PlanningMergers & AcquisitionsOperations ManagementOperation EfficienciesTechnical DesignLogisticsDatabase ModelingLarge Systems IntegrationLeadershipAccount ManagementSee 20+FinanceDirect MarketingRetailCross-functional Team LeadershipTeam BuildingStart-upsEntrepreneurshipBusiness DevelopmentStrategic PartnershipsE-commerceCRMTime ManagementPricingProduct MarketingContract NegotiationCompetitive AnalysisSales ManagementManagementStrategyCustomer Relationship Management (CRM)See lessHow's this translation?Great‚Ä¢Has errorsThanks for your help!Publicationswww.theralevehealth.comtargeted medical pharmaMarch 2016Theraleve‚Ñ¢ is the only natural supplement to use Targeted Cellular Technology¬Æ, our patented micro-nutrient delivery system that aids the absorption of the key anti-inflammatory ingredients found in Theraleve. The patented amino acid formula in Theraleve has been recommended by doctors for over a decade. Developed by pain management physicians, Theraleve gives your body the natural tools it needs to support healthy joint, muscle and nervous system function in the fight against pain and inflammation.*Authors: Joshua LevineView Joshua‚Äôs full profile to...See who you know in commonGet introducedContact Joshua directlyView Joshua‚Äôs Full ProfileNot the Joshua you‚Äôre looking for? View moreView this profile in another languageEnglishChinese (Simplified)GermanPeople Also ViewedElisabeth LassonPr√©sidente chez iLimousinesMelhem L SuccarPresident at Panda Inventions, LtdPeter SpiegelCEO at AquaTru, LLCdavid Le  BoudecDirecteur g√©n√©ral chez Hotel AriosoGunnar LentzMark FunkChief Financial Officer at Ideal Living GroupNoreen NobleMarketing & Branding Olivier LeloutreDirecteur de p√¥le Compass group chez Compass Group FranceCoralie LetellierDirectrice generale chez H√¥teli√®re palym sasSarina MichaelsDirector of New Business and Products at Ideal LivingPublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesFind a different Joshua LevineFirst NameLast NameExample:  Joshua LevineAdam Joshua LevineProfessional student at IUPUIUnited StatesJoshua LevineSenior Vice President of Restaurants & Bars at Hersha Hospitality ManagementUnited StatesJoshua LeVineCEO at FRAME DenimUnited StatesJoshua S. LevineFINRA Board of Governors and Senior AdvisorUnited StatesJoshua LevineSenior Vice President at AcuativeUnited StatesMore professionals named Joshua LevineLinkedIn member directory:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country




















 


Josh Levine | Professional Profile
 


























 









LinkedIn



















































Main content starts below.




Josh LevineExperienced Brand Management and Product Marketing LeaderLocationGreater Boston AreaIndustryConsumer GoodsCurrentVeteran BrandsPreviousGoogle, Procter & Gamble, US ArmyEducationHarvard Business SchoolRecommendations2 people have recommended Josh500+ connectionsView Josh‚Äôs full profile. It's¬†free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View Josh‚Äôs Full ProfileJosh‚Äôs ActivityBase*FEST Powered by USAA | CAMP LEJEUNE RECAPJosh sharedMarketers could learn so very much from this simple slide....Josh likedIncredibly grateful today for the men and women who...Josh likedThis article had me at "Carmen Sandiego and Oregon Trail"...Josh likedWhy My Dad Never Made it to V.P.Josh likedGoogle got it wrong. The open-office trend is DESTROYING...Josh likedSee all activitySummaryExperienced CPG brand builder and marketing leader for top global consumer and tech brands.  I approach end-to-end B2C and B2B marketing as a general manager, working hand-in-hand with cross-functional partners to always deliver on business goals - for the P&L and for the brand.  I have led marketing delivery of a billion-dollar brand through product launches, commercial innovation, media management and retail marketing.  I am passionate about developing and launching new products, go-to-market strategy, and building data-driven, consumer-first campaigns.  My experience includes five of Interbrand's 100 Best Global Brands.  Never satisfied with the status quo, I‚Äôm looking to join a brand that has ambitious growth goals and a passion to elevate their brand experience for a new generation of customers.Prior to my business career, I was fortunate to lead Soldiers and civilians as a Captain in the U.S. Army.  Through my diverse experiences, I have led organizations large and small, in a variety of functional roles including strategy, operations and logistics across North America, Europe and Asia.ExperienceFounder, Veteran BrandsVeteran BrandsJanuary 2017  ‚Äì  Present (7 months)Greater Boston AreaMarketing strategy consultancy specializing in veteran-run SMB's, brands targeting veterans and active military, and authentic American brands.  Practice areas: marketing strategy, branding, demand gen, new product development, digital marketing, UX/UI, retail and channel marketing.Senior Product Marketing ManagerGoogleJune 2014  ‚Äì  January 2017 (2 years 8 months)Greater Boston AreaLed B2B marketing campaigns and market research for Google Cloud products:‚Ä¢ Established market research function and led Google's first small business market segmentation.‚Ä¢ Led the strategic and creative development of global B2B marketing campaigns for G Suite (formerly Google Apps) and Gmail for a $500 M online business.‚Ä¢ Spearheaded acquisition marketing campaigns for desktop, mobile, social and traditional media, driving over 25% YOY growth.‚Ä¢ Established new marketing strategy and campaign processes to align business goals with all marketing activities and spending.‚Ä¢ Led all agency relationships for the business, including agency selection and evaluation.‚Ä¢ Established creative strategy and brand standards to drive cohesive customer experiences globally.Brand ManagerProcter & GambleMarch 2013  ‚Äì  June 2014 (1 year 4 months)Greater Boston AreaLed shopper marketing as part of 17-person sales team for a portfolio of 38 P&G brands (Tide, Pampers, Bounty, Old Spice, etc.) in the Club/Warehouse Channel, across health & beauty, household cleaners, paper products, baby and pet categories.  Developed in-store display, point-of-sale and direct marketing activities, and managed all agency creative and campaigns.Worked directly with a top national retailer CMO and merchandizers to develop Joint Business Plans, design co-marketing, and guide strategic initiatives.Senior Asst. Brand Manager - Gillette Global New ProductsProcter & GambleMay 2011  ‚Äì  March 2013 (1 year 11 months)Greater Boston AreaLed upstream design of new product innovations in male grooming, including market assessment, consumer research, product development and go-to-market tools.Driving force behind Gillette‚Äôs strategy to establish body grooming as a new category in male personal care and the development of Gillette BODY.  Chartered and led an eight-person cross-functional team to identify a $1 billion market opportunity; develop the product, brand, packaging, messaging, pricing, distribution and shelving plans; and create the multimedia ad campaign for the global launch.Directed $200 million program to design a new razor for low-income consumers in emerging markets.Asst. Brand Manager - GilletteProcter & GambleJuly 2009  ‚Äì  April 2011 (1 year 10 months)Greater Boston AreaManaged the day-to-day delivery of the $1.5B Gillette razor business in N. America, including campaign creation, media planning and all revenue and share reporting.Developed national campaigns and planned media across TV, digital, social, print, PR and consumer promotions for three successful product launches worth $350M, leading a team of two.Led sports marketing partnership and licensing with the NFL, MLB, NASCAR, the USO and the Armed Services.Captain, Civil Affairs OfficerUS ArmyFebruary 2008  ‚Äì  October 2008 (9 months)Duties included country analyses, economic development planning, infrastructure assessments and population studies in regions where U.S. forces were deployed.  This tour was a one-time recall to active duty by Presidential authorization.New Products ManagerBose CorporationJune 2007  ‚Äì  February 2008 (9 months)Product manager for next-generation wireless and mobile speaker systems.Defined product concept and led product development team for the Bose SoundLink¬Æ, Bose's first wireless portable music product.Led mobile electronics landscape assessment and Bose‚Äôs five-year strategy development for mobile audio products.Managed go to market activities for Bose MusicMonitor computer speakers and Lifestyle V-series home theater products.Product Management Intern - Monogram AppliancesGeneral ElectricJune 2006  ‚Äì  August 2006 (3 months)Louisville, Kentucky AreaAs a MBA intern,¬ï designed consumer rebate program and new pricing strategy for GE Monogram appliances.  Managed redesign of brand website (www.Monogram.com) to improve branding and user experience (UX).Captain, Brigade Operations OfficerUS ArmyJanuary 2004  ‚Äì  May 2005 (1 year 5 months)Brigade Operations Officer, 1st Armor Training Brigade‚Ä¢ Managed fifty-person operations group responsible for day-to-day training of 15,000 combat soldiers annually.‚Ä¢ Developed tactical plans and directed operational exercises to train 2,000 soldiers for contingency operations including natural disasters, terrorist attacks, and civil support missions.‚Ä¢ Designed training programs and resourcing plans for the preparation of Army Reserve and National Guard units deploying to operations in Iraq and Afghanistan.‚Ä¢ Coordinated all security, intelligence, planning, and resource allocation operations for seven subordinate organizations.Captain, Battalion Logistics OfficerUS ArmyDecember 2002  ‚Äì  December 2003 (1 year 1 month)Battalion Logistics Officer, 1-72 Armor Battalion‚Ä¢ Led 10-soldier team that managed transportation, supply, maintenance, and medical support for a 650-soldier tank battalion.‚Ä¢ Managed a $12 million operating budget; including centralized procurement, inventory management and accounting of $212 million of capital equipment.‚Ä¢ Earned six commendations for excellence in accounting, regulatory compliance and procurement activities.1st Lieutenant, Company Executive OfficerUS ArmyFebruary 2002  ‚Äì  December 2002 (11 months)Company Executive Officer, 1-4 Infantry Regiment‚Ä¢ Led 40-soldier administrative cell and served as second in command of a 330-soldier infantry support company.‚Ä¢ Created and supervised maintenance tracking and quality control systems for the unit‚Äôs 111 vehicles and 400+ weapons, resulting in 95% equipment readiness rate and 100% accountability.‚Ä¢ Managed Army dining facility, with a staff of 6 soldiers and thirty German civilians, responsible for feeding 1,000 people daily.2nd Lieutenant, Platoon LeaderUS ArmyNovember 2000  ‚Äì  February 2002 (1 year 4 months)2nd Lieutenant, Armor Platoon Leader‚Ä¢ Led, trained and maintained a tank platoon of thirty soldiers with thirteen tanks worth $26 million.  Responsible for all individual and unit tactical training in preparation for combat operations and peace support missions.‚Ä¢ Commanded military exercises over 16 months at the Army‚Äôs Combat Maneuver Training Center to train United States and NATO armies in Europe.  Recognized for 12 straight months with the highest success rate and effectiveness of all 12 peer units.‚Ä¢ Directed base security force mobilization & round-the-clock security operations following terrorist attacks of Sep. 11, 2001.SkillsCross-functional Team LeadershipStrategyMarketing StrategyLeadershipProduct MarketingProduct DevelopmentBrand ManagementMarket ResearchBusiness StrategyOperations ManagementVeteransCompetitive AnalysisManagementMarketingProduct ManagementSee 9+Marketing ResearchSegmentationStrategic PlanningCustomer InsightConsumer ProductsDigital MarketingMarketing ManagementAdvertisingBusiness DevelopmentSee lessHow's this translation?Great‚Ä¢Has errorsThanks for your help!EducationHarvard Business SchoolMBA, Marketing & General ManagementMBA, Marketing & General Management2005  ‚Äì  2007Areas of focus included marketing, general management and entrepreneurship.Activities and Societies: Business of Sports Club, Armed Forces Alumni Association, Outdoors ClubPrinceton UniversityBSE, Mechanical & Aerospace EngineeringBSE, Mechanical & Aerospace Engineering1996  ‚Äì  2000Thesis and design project in electric propulsion.  ROTC Distinguished Military Graduate.Activities and Societies: Army Reserve Officer Training CorpsVolunteer Experience & CausesVolunteerBig Brothers Big Sisters of AmericaPresentChildrenVolunteerPalo Alto VA HospitalPresentHealthManagement ConsultantCommunity Action PartnersPresentChildrenCauses Josh cares about:ChildrenHuman RightsDisaster and Humanitarian ReliefPoliticsScience and TechnologyRecommendationsA preview of what LinkedIn members have to say about Josh:Josh has a great head for business, and consumers in particular.  As the CEO of To The Fallen Records, he helped me design a new and innovative marketing strategy, including enhanced brand positioning and new methods of distribution channel management.  Over the period of time Josh has been consulting for TTFR, our sales have increased by 200%.  Lastly, Josh generated pro forma financials and prepared a business valuation of TTFR in preparation for investor fundraising.  His help in reworking my business strategy has been invaluable!See moreSee lessI worked with Josh during his time in product marketing at Bose, and simply put - Josh is an extremely smart individual with fantastic business and technical perspective.  I have great confidence that he could be successful in a number of roles.See moreSee lessSign up to see who recommended JoshGroupsDisabled American VeteransBrand ManagementP&G Alumni Network - Global (Procter & Gamble)US Military Veterans NetworkAlumni & Friends of Princeton ROTCP&G HBS and Harvard Recruiting NetworkChief Marketing Officer (CMO) Network - #1 Group for CMOsSee 4 moreBrand Managers NetworkSocial Media MarketingProduct Marketing ManagersHarvard Business School Alumni (Official)See lessView Josh‚Äôs full profile to...See who you know in commonGet introducedContact Josh directlyView Josh‚Äôs Full ProfileNot the Josh you‚Äôre looking for? View moreView this profile in another languageEnglishPublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesFind a different Josh LevineFirst NameLast NameExample:  Josh LevineJosh LevineAuthor | Coach | Trainer | EntrepreneurUnited StatesJosh LevineBrand partnerships for Linkin Park + Culture marketing for consumer brands + Host of Rebel RadioUnited StatesJosh Levine ‚ö°Ô∏èAuthor | Speaker | EducatorUnited StatesJosh LevineUnited StatesJosh Levine, CFP¬Æ, CAP¬ÆFounder & CEO - Cornerstone Family Office, LLCUnited StatesMore professionals named Josh LevineLinkedIn member directory:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country























Joshua Levine's profile on Product Hunt




























Product HuntThe best new products, every dayAsk‚óè|Log InSign up¬†Joshua Levine#32089@jslevinenyc26Following31FollowersFollow37 UpvotesMade With ARKitHand-picked curation of the coolest stuff made with ARKitTech+ 2¬†save¬†1045¬†15WikitribuneEvidence based journalism, from the founder of WikipediaNews+ 2¬†save¬†1373¬†39Caf√© Wifi Search üîçFind great caf√©s to work from, worldwide.Productivity+ 6¬†save¬†801¬†35Cassette for iOSThe best way for designers to record & share user interviewsCustomer communic...+ 4¬†save¬†1231¬†126Amazon ChimeFrustration-free video calls. Amazon's Skype competitor.Video Streaming+ 5¬†save¬†1892¬†115PingBusiness cards suck, so we help you make real connections.Tech¬†save¬†1367¬†131Google VoiceRinging in 2017 üìûiPhone+ 4¬†save¬†1198¬†60BizplanModern business planning for startupsProductivity+ 3¬†save¬†1980¬†80Product DisruptA design student's list of resources to learn Product DesignDesign Tools+ 1¬†save¬†1396¬†27Slack Video CallsTalking face-to-face with your team is just one click awayVideo Streaming+ 1¬†save¬†1788¬†89ListenA smart phone numberProductivity+ 3¬†save¬†861¬†158‚ù§‚ù§‚ù§.wsEmoji domain registrationTech+ 2¬†save¬†604¬†152MaterialetteA material design color palette on macOS / Windows / LinuxDeveloper Tools+ 4¬†save¬†449¬†7RoadmapCustomer Feedback & Product RoadmapsProductivity+ 6¬†save¬†571¬†27ViewedItRecord your screen, share & know instantly when people watchProductivity+ 9¬†save¬†664¬†126Who Runs ThisEasily find the parent company owning a siteChrome Extensions+ 2¬†save¬†273¬†17Lose It!Snap a photo of your food to get nutritional factsProductivity+ 4¬†save¬†444¬†28TroopsSlackbot that makes CRM easy and IntelligentArtificial Intell...+ 4¬†save¬†574¬†60Google AlloSmart messaging app that helps you say more and do more.iPhone+ 5¬†save¬†2979¬†169Google TripsExploring the world with all your travel info in one placeiPhone+ 4¬†save¬†2499¬†82Share this profile






 


Joshua Levine
 | LinkedIn
 





























 









LinkedIn



















































Main content starts below.




Joshua LevineSenior Vice President at AcuativeLocationGreater New York City AreaIndustryInformation Technology and ServicesCurrentAcuativePreviousCompuCom Systems, VanguardMS, Appilog Inc.EducationAmerican UniversityWebsitesAcuative500+ connectionsView Joshua‚Äôs full profile. It's¬†free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View Joshua‚Äôs Full ProfileJoshua‚Äôs ActivityLooking for an new opportunity? Look no further!!! We have...Joshua likedRegistration is open for an exclusive Ciena and Acuative...Joshua likedPhotoJoshua likedA big, exciting day for PCM Canada.  It was a pleasure to...Joshua likedI am so excited to announce that Jim Dixon is joining our...Joshua likedUNLOCKING THE POTENTIAL OF DYNAMIC IT SERVICES
April 21,...Joshua likedSee all activitySummarySenior IT Executive with 20+ years‚Äô experience leading sales and marketing, operations, product and service management, technology initiatives, and merger/integration activities ‚Äì generating millions of dollars in revenues and profits. Excel in business planning, implementation, and leveraging product/service technologies to achieve innovative, cost-effective technology solutions. Successful at directing the evolution of technical and non-technical solutions from concept through execution, constantly managing the needs of the customer, the team, and the project / program. Expert at aligning merger and integration activities with corporate objectives to enhance productivity, while realizing costs synergies. Areas of expertise include:‚ñ™ Business Planning & Execution‚ñ™ Strategic Partnerships‚ñ™ Program & Project Management‚ñ™ Marketing & Sales Initiatives‚ñ™ IT Integration Initiatives‚ñ™ Product & Market Launch‚ñ™ Startup Operations (IT)‚ñ™ M&A and Integration Activities‚ñ™ Capital & Budget ManagementExperienceSenior Vice PresidentAcuativeJanuary 2017  ‚Äì  Present (7 months)Greater New York City AreaA global provider of technology solutions, Acuative simplifies management of the entire IT/network lifecyle, assisting our clients in the service provider, enterprise, finance, retail, and public sector markets in achieving their desired business outcomes.Bridging the gap between business strategy and technical implementation, we develop and execute technology strategies that align with our clients' business goals. Our portfolio includes consulting, field, technical, and managed services for data centers, unified communications/IPT, wireless/mobility, security, infrastructure management, and IT service management.Vice President - Cloud, Security & Remote Infrastructure ManagementCompuCom SystemsSeptember 2007  ‚Äì  November 2016 (9 years 3 months)Vanguard Managed Solutions specialized in providing enterprise customers with managed cloud, network and security services, from assessment and strategy to implementation and management. The division was acquired by CompuCom Systems, Inc. in September 2007.Retained, following CompuCom‚Äôs acquisition of Vanguard Managed Services Division, to (1) lead the integration team, (2) introduce Vanguard‚Äôs S&RIM services across CompuCom‚Äôs new and existing customer base, (3) and introduce CompuCom‚Äôs portfolio of services into Vanguard‚Äôs existing customer base and key channel partners. Manage a team of 6 account executives across the U.S. Led the 2007 sale of Vanguard Managed Services to Court Square Capital (private equity firm) which in turn merged it into CompuCom Systems, Inc. Involved in all areas of service offer development, working closely with the sales delivery team to ensure proper implementation of services and increase overall customer satisfaction.President / COOVanguardMSOctober 2004  ‚Äì  September 2007 (3 years)Selected to lead a services division with full accountability for P&L, vision, strategic planning and direction, business development, sales and marketing, product/service launch, customer relations, and key account management. Built and led a team of more than 155 employees. Oversaw various departments and related budgets that include finance, network operations center, information technology, professional services, sales and marketing, service deployment, solution development, and customer service. Reported to the Board of Directors.VP of Business DevelopmentAppilog Inc.January 2004  ‚Äì  October 2004 (10 months)Appilog Inc. was a software technology firm specializing in developing / implementing solutions to help clients manage IT assets.   Hired by the CEO following the successful completion of consulting assignment to identify channel partners and help establish the company‚Äôs U.S. Sales & Marketing Group. Charged with preparing Sales & Marketing for eventual company sale, leveraging strategic relationships to establish and grow distribution partners. Worked closely with account managers and engineers to ensure solutions met customer requirements. Carried out business plans and policies meet and/or exceed the company‚Äôs operational and financial objectives as set forth by the Board of Directors. The company was sold to Mercury Interactive in July 2004.President and COOApplied Technology Consulting GroupNovember 2001  ‚Äì  January 2004 (2 years 3 months)Led all sales, marketing, and business development initiatives to secure distribution rights for technology export in the Chinese marketplace. Researched and selected long-term project-based consultants for financial services firms. Worked closely with investment partners to identify and evaluate potential acquisition and/or investment opportunities.Launched new technology products from conception to implementation for the China market that included VPN appliance, custom data compression software, and application / database management software.  Established and maintained joint-venture partnerships with a software start-up firm to develop high-margin technology products for the financial services industry.Founder / Chief Executive OfficerGenosys Technology ManagementFebruary 1999  ‚Äì  November 2001 (2 years 10 months)Oversaw all business functions that included sales, finance (P&L), strategic planning , customer/strategic relations, capital projects, product launch, and business development / market penetration activities. Defined corporate strategy, sales, and marketing direction to target large-scale Fortune 2500 companies. Selected the global senior management team. Raised over $16M in venture capital funding. Identified and targeted key market opportunities valued over $22M.Director of SalesICON CMT1998  ‚Äì  1999 (1 year)Senior Sales ManagerMCI Telecommunications1996  ‚Äì  1998 (2 years)Global Account ManagerSprint Nextel1985  ‚Äì  1996 (11 years)SkillsBusiness DevelopmentStrategic PlanningStart-upsStrategic PartnershipsNew Business DevelopmentBusiness StrategyProgram ManagementOutsourcingProduct ManagementProject ManagementOperations ManagementCross-functional Team LeadershipCloud ComputingHow's this translation?Great‚Ä¢Has errorsThanks for your help!EducationAmerican UniversityBachelor of Science, International BusinessBachelor of Science, International Business1985Activities and Societies: Alpha Tau Omega, Alpha Tau Omega FraternityGroupsExecutive Talent: Insights for the C-Suite, by AESCOI Cyber Security Special Interest GroupTelecoms Professionals: IoT, LTE, M2M, OTT, Internet of Things, Mobile, TelecomAny DisasterNew baby and childrens productsNew York Venture CommunityInformation Security Careers Network (ISCN): Cyber/CISSP/CCNA/PCI/Data/Network/Hacking/cloud jobsSee 7 morePrivate Wealth ManagementInformation Security CommunityCloud Security AllianceThe Family Office Club - #1 Largest Family Office Association | Ultra-Wealthy Wealth ManagementLullabuymeAmerican University AlumniIT Core InfrastructureSee lessView Joshua‚Äôs full profile to...See who you know in commonGet introducedContact Joshua directlyView Joshua‚Äôs Full ProfileNot the Joshua you‚Äôre looking for? View moreView this profile in another languageEnglishChinese (Simplified)GermanPeople Also ViewedDave BorgeseVice President, Sales at PCM Inc. Robert McDanielVice President, Service Delivery at AcuativeBill D'OnofrioVice President - ITO Business Development at CompuComKevin ShankChief Executive OfficerRobert Foley, Jr.President at AcuativeRuth Ann CooperManaged Mobility Guru ‚ô¶ Expense Management (TEM/WEM) Solutions Expert ‚ô¶ Global IT Managed Services ConsultantScott WardSVP and General Manager at Zones, Inc.Diana MeachamMarco GiuntaSenior Vice President US Sales at CompuComMichael DiamondDirector of Sales Operations and Business DevelopmentPublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesFind a different Joshua LevineFirst NameLast NameExample:  Joshua LevineAdam Joshua LevineProfessional student at IUPUIUnited StatesJoshua LevineSenior Vice President of Restaurants & Bars at Hersha Hospitality ManagementUnited StatesJoshua LeVineCEO at FRAME DenimUnited StatesJoshua S. LevineFINRA Board of Governors and Senior AdvisorUnited StatesJoshua Levine, Ph.D.Board Certified Behavior AnalystUnited StatesMore professionals named Joshua LevineLinkedIn member directory:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country




















Accuray's (ARAY) CEO Joshua Levine on Q2 2017 Results - Earnings Call Transcript | Seeking AlphaSign in / Join NowGO¬ªAccuray's (ARAY) CEO Joshua Levine on Q2 2017 Results - Earnings Call TranscriptJan.31.17 | About: Accuray Incorporated (ARAY) Accuray Incorporated (NASDAQ:ARAY)
Q2 2017 Earnings Conference Call
January 31, 2017 04:30 PM ET
Executives
Doug Sherk - Founder and CEO, EVC Group, IR
Joshua H. Levine - President and CEO
Kevin Waters - SVP and CFO
Analysts
Josh Jennings - Cowen & Co.
Anthony Petrone - Jefferies & Co.
Brandon Henry - RBC Capital Markets
Operator
Good day, ladies and gentlemen, and welcome to the Accuray Incorporated Fiscal Second Quarter 2017 Earnings Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder this conference is being recorded. I would like to introduce your host for today‚Äôs conference, Doug Sherk. Sir, you may begin.
Doug Sherk
Thank you, Tim and good afternoon, everyone. Welcome to Accuray's conference call to review the financial results for the quarter ending December 31, 2016, which is the company‚Äôs second quarter of its fiscal 2017 year as well as recent corporate developments. 
Joining us todays are Josh Levine, Accuray's President and Chief Executive Officer; and Kevin Waters, Accuray's Senior Vice President and Chief Financial Officer. 
Before we begin, I'd like to remind you that during our call today -- the call includes forward-looking statements that involve risk and uncertainties, including statements regarding our business plans and strategies as well as our outlook for fiscal 2017. There are a number of factors that could cause actual results to differ materially from our expectations, including, but not limited to, risks associated with the adoption of CyberKnife, TomoTherapy, Onrad and Radixact Systems; commercial execution; future order growth; future revenue growth and macroeconomic factors outside of the company's control. 
These and other risks are more fully described in the press release we issued after the market close this afternoon, as well as in our filings with the Securities and Exchange Commission. The forward-looking statements on this call are based on information available to us as of today's date and we assume no obligation to update any forward-looking statements. 
During the question-and-answer today, we request that questioners limit themselves to two questions and then re-queue with any follow-up questions. We thank everyone in advance for their cooperation with this process.
And with that out of the way I'd like to turn the call over to Accuray's President and Chief Executive Officer, Josh Levine.
Joshua H. Levine
Thanks Doug. Good afternoon everyone and thank you for joining on today's call. Following the market close today we reported second quarter financial results, highlighted by strong growth for both gross orders and backlog. Gross orders for the quarter increased 17% year-over-year to $78.5 million, while our backlog grew 16% year-over-year to a record $426.2 million. We believe our progress is evidence that the catalysts driving order growth discussed with you over the last several quarters are beginning to take hold. These catalysts include a meaningful replacement cycle for Accuray products and greater recognition by both existing and new customers that our company's product portfolio offers increased versatility and functionality for customers. 
Over the next few minutes I'd like to provide more color on the most important of these catalysts, before turning the call over to Kevin for a more detailed review of our financial performance and full year outlook. First, as many of you know, we are entering the early phase of a multi-year replacement cycle of approximately 200 TomoTherapy and CyberKnife systems that will reach their tenure in service dates within the next 36 months. While we anticipate replacements will generally average 10% to 20% of orders on an annual basis, the results in the second quarter were north of that range with the largest number of replacements occurring in the US market. 

At the end of our first fiscal quarter we communicated we had secured commitments for several replacement orders in Q1 that were indeed finalized in the second quarter. We are optimistic about the replacement sales momentum continuing. When we look at the full file of our installed base we have a mix that leans heavily towards large multi-bunker [ph] academic institutions where many have our earlier generation Tomo and CyberKnife systems, who will therefore benefit from the significantly improved functionality, versatility and reliability of our newest devices. 
Many of these institutions are led by key opinion leaders who are engaged in research and who recognize the value of improved workflow and efficiency associated with our latest generation products. Our view is bolstered when we look at an installed customer base that is increasingly satisfied with the performance and reliability of our systems. 
Related to this earlier in the month, we announced that Accuray radiation therapy systems continue to set the industry standard for customer satisfaction once again receiving MD Buyline's highest Composite Overall User Satisfaction rating among radiation treatment delivery systems in the US. In fact most recent ratings report for calendar Q4 showed that Accuray radiation therapy products have now achieved the highest composite rating among industry peers for 11 of the past 12 quarters. The MD Buyline survey results are consistent with the net promoter scores by IMV ServiceTrak, where Accuray was rated number one in overall system performance. We believe these improvements in system performance reliability and ease of use are helping to drive gross order and backlog growth. 
Additionally, future order growth benefited from an improved order mix of our CyberKnife system. We continue to see the majority of CyberKnife system orders configured with a Multileaf Collimator, which not only increases the versatility and speed of the system but also enhances the average selling price and margin profile. While it's probably too early to attribute the second quarter CyberKnife order strength to recent clinical data, we do believe that CyberKnife SBRT study for low and intermediate risk prostate patients that was presented at ASTRO In September will enhance the strategic positioning and clinical validation of CyberKnife as an effective full body radiosurgery device, supporting momentum and order growth going forward. 
Additionally, while the majority of our Q2 CyberKnife orders in the US were replacement cells, throughout the rest of the world we saw a healthy mix of both replacements and new CyberKnife customers, which speaks to the expanded versatility of our latest generation CyberKnife platform. Transitioning to Radixact, future orders also benefited from the early rollout of our new Radixact System, the next generation of our TomoTherapy platform. As we announced the first patient treatments had occurred in a number of our early reference site accounts -- site accounts in the U.S. and Europe.
Customer feedback regarding the performance of the new Radixact System at those locations was extremely positive with regards to speed, efficiency and image quality of the device. Customers were also pleased with the performance of our new precision treatment planning software and its adaptor [ph] planning and retreatment capabilities. Additionally in Q2, we continued our multi-system momentum with the booking of another multi-system order for three Radixact units with the prestigious Hong Kong Sanatorium & Hospital. 
Regarding Onrad, our new value product segment offering in China, we remain on track with regards to our initial launch. As we have discussed previously regarding Onrad, a large element of the selling process is dependent on successful participation in provincial level tender processes. Based on the tender process timelines, we expect initial order uptake for Onrad to begin late in fiscal Q3 or early Q4 with further order ramp continuing from there forward.

While we‚Äôre pleased that the halfway mark of our fiscal year to be above our internal forecast for gross orders and backlog, we recognize that potential variability in terms of outcomes, timing in two key areas, potentially create some revenue uncertainty in the second half of this fiscal year. Let me touch on these two areas, revenue conversion and the timing of Class A license issues in China in more detail.
First, we continue to see modestly extended revenue conversion times, due to a higher mix of international distributor orders in our backlog. We experienced that increasing trend in the percentage of our backlog related to distributor orders which increased 6% since fiscal year-end 2014. The impact of working with independent distributors in general is that we have less direct control over the timing in converting these orders to revenue versus our direct sales. Process critical activity such as site planning, installation planning and coordination of contractors, when the distributor has primary responsibility for system installation, results in less direct line of site with the end user facility and limits our ability to manage all elements of the installation process, which can result in timing variability and delays.
The second area of potential impact is the timing uncertainty of a final announcement concerning Class A radiotherapy licenses from the Chinese Ministry of Health. Given the delays in this announcement over the past several quarters, it‚Äôs becoming more difficult to predict when the Class A license program specifics will be finalized.
Our internal assumption supporting our second half fiscal 2017 revenue forecast is tied to a final announcement regarding Class A radiotherapy licenses coming by the end of our fiscal third quarter. But given the delays we‚Äôve seen and the uncertainty of timing going forward, we believe it‚Äôs prudent to remind you of the potential impact of our second half revenue outlook related to continued delays.
With that said, we remain very confident in the China market opportunity overall and our competitive positioning in the class A radiotherapy segment. And with that I‚Äôd like to turn the call over to Kevin.
Kevin Waters
Thank you, Josh and good afternoon everyone. We ended the second quarter with backlog of $426.2 million, up 16% over the prior year. Backlog included gross orders of $78.5 million and net orders of $54.1 million, reflecting age outs of $19.9 million and one cancellation for $3.6 million. Age outs in the quarter were anticipated and consistent with the guidance we provided in October.
In addition, currency negatively impacted net orders by approximately $1 million in the second quarter. Josh already highlighted the factors contributing to our strong gross order performance, including replacement sales above historical averages, improved mix, of both new and replacement CyberKnife orders and a multi-system Radixact order. All of these items led to significant gross order growth in the quarter and we are approximately $10 million above our guidance for the first half of fiscal 2017.
First half of fiscal 2017 gross order performance translated into 16% year-over-year growth in our backlog. As we look out 12 months to 24 months when these systems are installed our backlog could translate in to product revenue growth rate greater than our rate of product growth in fiscal 2017.
Turning now to our income statement, total revenues for the second quarter were $87.5 million compared with record levels of revenue of $108.9 million in the year ago period. On a sequential basis, revenues were up slightly over the first quarter and we continue to anticipate a linear progression of revenue as we move through the balance of the year. I‚Äôll provide more detail on the metric shortly. Product revenues for the quarter were $35.4 million. We performed above our expectations for the quarter in the U.S. and Japan. This was offset by below plan performance in Europe which is primarily attributable to the marginally extended conversion to revenue times that Josh highlighted. 

Service revenues for the second quarter were $52.1 million compared with $53.2 million in the year ago period, which was in line with our expectations. 
Turning to gross margins, our overall gross margin for the quarter was 36%, down 320 basis points compared with the prior year period and flat on a sequential basis. Product gross margins in the quarter decreased 620 basis points over the prior year period to 35%, primarily driven by the lower overall unit sales volume as well as product and channel mix. Product and channel mix continue to be the most significant factor in regards to quarterly fluctuations in product margins. As with the first fiscal quarter we again experienced a higher concentration of TomoTherapy Systems to revenue as compared to CyberKnife. In prior year we averaged an approximate one-to-one ratio of CyberKnife to TomoTherapy revenues. And in the first six month of 2017 this mix has been two to one in favor of TomoTherapy.
I would also highlight that overall pricing in the first half of 2017 has been relatively stable to the year ago period and within our expectations. We continue to anticipate an improvement in product gross margin in the second half of the fiscal year on higher revenue volumes and more favorable mix that should gross margins on a full year basis to be approximately flat as compared to the year ago period. 
Service gross margin in the fiscal second quarter of 36% were essentially flat with the year ago period. We continue our focus on improved parts reliability and cost management and anticipate full year fiscal 2017 service margins to be at or above fiscal 2016, which were 36%. Operating expenses for the quarter decreased 15% from the prior year period to $36.2 million. The $6.5 million decline included a $3 million decrease in R&D, a $1.2 million decrease in selling and marketing and the $2.3 million decrease in G&A primarily due to lower legal expenses. The contributing factor behind the lower operating expenses across all categories was incentive compensation and commission expenses as a result of lower sales volume. 
Adjusted EBITDA was $1.8 million compared to $6.8 million in a year ago period. We continue to have a particularly high level of confidence in our ability to effectively manage costs, which I'll touch on in our guidance shortly. 
Let‚Äôs now turn to the balance sheet. We had $108.4 million of cash and investment at December 31, 2016. The $16 million sequential decrease in cash from the first quarter is primarily due to the timing of revenue collections which can be seen in the $14.7 million increase in accounts receivable. Additionally we used $6 million to pay down current debt balances.
Turning to our capital structure, we remain focused on strengthening our balance sheet by reducing the potential dilution associated with our convertible debt. We will report to you on our progress as development merits and we continue to believe accurate annual financial performance and growing backlog will provide greater options and flexibility. 
Turning now to our annual guidance for fiscal 2017, we are today affirming the guidance originally provided back in August for all metrics except operating expenses as follows: Year-over-year growth of approximately 5% for gross orders; a revenue range of $410 to $420 million. Although our first half performance leads us to believe the lower end of the range is more likely independent primarily on two variables that I‚Äôll explain shortly. We‚Äôre expecting adjusted EBITDA range of $32 to $38 million. Additionally given first half operating expense levels were below expectations, we are lowering full year operating expenses to be down approximately 3% as compared to fiscal 2016. 
Given the lower operating expenses, we do remain confident in our ability to achieve our adjusted EBITDA range which would represent year-over-year growth of between 30% and 55%. With regard to full year revenue, implicit in our revenue guidance are two variables that will impact our ability to achieve the revenue range. Josh mentioned our internal assumptions around expectations of a Class A license announcement out of China in the third quarter. China Class A revenues comprise approximately $10 million to $15 million to our second half fiscal 2017 revenue guidance. Additionally, almost all of the China revenue contribution is now anticipated to be in our fourth quarter. 

Our revenue guidance also anticipates the shipments or installation of several distributed orders within the timeframe expected when these orders were entered in the backlog. At this time we have no reason to believe the conversion of these orders to revenue will experience timing delays. As with China, our firm belief is that the conversion to revenue is purely a timing issue. Further we would anticipate closing out fiscal 2017 with product system backlog of approximately $440 million, which would be above the overall market growth rate. We also anticipate Q3 age outs to be approximately $12 million. We anticipate that age outs as a percentage of backlog for the full year of fiscal 2017 will be an improvement over fiscal 2016's level of 13%. 
And with that I would now like to hand the call back to Josh. 
Joshua H. Levine
Thanks, Kevin. Before we open the call up to your questions, I'd like to thank the entire Accuray team for their focus and contribution to our performance in second quarter. Our company's commitment to the important work we are doing in improving the lives of cancer patients by providing leading edge treatment solutions remains central to our mission. 
Now operator we're ready to open the call up for questions. 
Question-and-Answer Session 
Operator
Thank you. [Operator Instructions] And our first question comes from Josh Jennings from Cowen & Company. Your line is open. 
Josh Jennings 
Hi good evening, thanks gentlemen. I was hoping to ask you a few questions on the sales funnel. Clearly the replacement cycle has set up nicely. And any high level thoughts on how you're feeling about the de novo customer funnel at mid-year versus the beginning of the year. Then on Radixact, and one of the promise of the platform that it will more fully open up to single and dual vault segments of the market and can you talk about the early Radixact funnel and the mix of single and dual vault centers within it. And then lastly you secured another multi-system order in fiscal 2Q. Does the funnel include more potential multi-system orders as well? 
Joshua H. Levine
So Josh I'll take in, I guess in that sequence that the question were given. Let me talk a little bit about replacement cycle in general. As we've characterized in the past the primary geographic focus is our US market and Western Europe across both platforms. If you think about just the performance, let's say in Q2 and the contribution, the bigger contribution in terms of product mix from a CyberKnife standpoint, right now across the entire installed base that's kind of coming into replacement cycle on CyberKnife, less than 20% of that installed base actually has the latest generation device. 
So when you think about the opportunities for M6, MLC equipped people that are looking to build full body radio surgery programs, we think we have a lot more ground to cover in terms of opportunities inside the installed base and that's represented by replacement cycle. We talked a little bit about product advantages on both platforms. I mean we have the basis here for confidence really comes from a better performing product on both platforms, better functionality, better speed, better throughput, better reliability. And those things really translate into expanded clinical versatility in the minds of customers but also a growing addressable market opportunity for us. 
So I'm pretty bullish on the continuation of momentum in the replacement sales piece in both the US market and Western Europe.
Kevin Waters
Yeah I could take your single and dual vault question, we continue to experience the majority of our orders for Radixact and TomoTherapy in single and dual vault, which has been really running now for probably last four or five quarters, Josh. So that trend continued in the second quarter. 

Joshua H. Levine
Josh, I think the last question you had was around Radixact, and kind of funnel and what our view is right now from an early assessment? We are in still in this current quarter, ramp and monitor [ph], which is really kind of a reference site installation optimization exercise that essentially makes sure that we‚Äôre creating the very best reference sites we can and understanding elements of installation that are specific to the new platform. 
That program is not completed until the end of this quarter, so the fiscal third quarter but quite frankly as you can see it‚Äôs not standing in the way of us taking orders for Radixact. So we‚Äôve got sites in both the U.S. and Europe that are reference sites that we‚Äôve already taken to revenue and that are all treating patients today. And again we expect that they‚Äôll be completed with ramp and monitor as a phase by the end of the third quarter but generally the feedback from those customers that now have patient treatment experiences with the new system has been really positive, very strong feedback, positive feedback about speed, product performance and so much this is exceeding their expectations quite frankly. 
So we‚Äôve again a stronger sense that we‚Äôve got with Radixact, a true workhorse product and a product that quite frankly is going to really meet the needs of a lot of customers. 
Josh Jennings 
Thanks for that. Sorry for the multi-pronged question. Just one follow-up, just on the replacement cycle, I don't -- sorry if you guys commented on this in your prepared remarks but can you give us an idea whether you‚Äôre maintaining that replacement conversion rate? And then lastly with Radixact and with the next generation CyberKnife with the InCise MLC, are you seeing any customers move up their replacement timeline to have the latest and greatest Accuray technology platform earlier than say 10 years? Thanks for taking the questions guys. 
Kevin Waters
So I'll start. I will let Josh come -- follow-up on the timing. We did see in the second quarter, Josh above, I‚Äôd say historical performance on the replacement cycle. We have said that you should expect in fiscal 2017 for us to be in the 10% to 20% range as a percent of total orders. We were north of that in the second quarter. But I don‚Äôt get too excited about looking at it on a quarterly basis. I think for fiscal 2017 we‚Äôre still comfortable with placements being somewhere in the 10% to 20% range of total orders. 
Joshua H. Levine
Josh, on the accelerated timing, if you will, part of the question, again if you look at the profile of the typical location that we have our installed base equipment and you‚Äôre talking about large multi-bunker academic institutions, generally a more complex case mix of patients that end up being treated in those institutions, and in many cases people that lead those departments and those -- the radiation oncology practice, if you will, at those medical centers, are pretty well-known key opinion leaders, people that are still actively involved in research with those patient populations and our devices. So there‚Äôs generally a desire to have, what I would characterize as the latest and greatest, if you will in terms of our equipment. 
I think maybe in certain cases you see people that would -- and have the capability from a budget and a flexibility standpoint to be able to go, to upgrade, perhaps sooner than a ten year replacement cycle but our expectations are that it isn't necessarily that that‚Äôs going to happen on a routine basis or a highly predictable basis. 
We‚Äôve got a lot to keep us busy quite frankly, just at the level of replacement sale opportunity in front of us. Again it‚Äôs 200 plus systems across CyberKnife and TomoTherapy, on both platforms and again I think we have a fairly robust view of the momentum if you will of replacement sales continuing. 

Josh Jennings 
Thanks for those answers. Appreciate it. 
Joshua H. Levine
Thanks Josh.
Operator 
And our next question comes from Anthony Petrone from Jefferies. Your line is open. 
Anthony Petrone
Thanks and good afternoon. Maybe I‚Äôll start with a higher level question just on the market landscape and then move into a couple on guidance. But maybe just Josh and Kevin if you provide an update on the competitive landscape, just as it relates to elect and vary and maybe the similarities and differences around the landscape heading into calendar year 2017?
Kevin Waters
So I‚Äôll start Anthony. I think again if you look at where, certainly where our replacement sales opportunity resides, again you've got heavy concentration in the U.S. and Western Europe. In the U.S. market the primary people we're competing against is Variant. Probably seven out of the ten bunkers that our sales people drive past have a Variant device of one form or another running in those vaults. So I'd say it's a very -- from a competitive scenario, it's a very Variant-centric kind of landscape. 
I think we're doing a really good job of maintaining and retaining our existing bunkers. And we are showing that with improved functionality and product capability and reliability we've got -- in a competitive sense, we've got the ability to convince single and dual vault locations that Tomo and now Radixact are really viable options for them, where overtime if you look back over the last four-five years that quite frankly historically wasn't the case. 
So I think we're feeling pretty good about the competitive dynamics. Again we're not wining at 100%, we're not going to win at 100%. But I think we're being a more viable competitor quite frankly today, than we've been at any point of time in my experience at Accuray.
Anthony Petrone
That's helpful and maybe just to clarify from a bunker size standpoint is Tomo and Radixact similar to sort of existing dimensions for the majority of those installed Variant bunkers?
Kevin Waters
Yeah, they would certainly be more characteristic of a relatively easy substitution, relatively minimal bunker modification would be required. So that certainly helps the discussion. 
Anthony Petrone
Okay. And then just on guidance, you've mentioned distributor orders. I'm just trying to get a sense of the difference in timing of revenue recognition sort of when you have a distributor order versus a direct sales order. And maybe just the last question would be what do age outs and cancellations look like with respect to distributor orders versus direct orders? Thanks. 
Kevin Waters
Yeah, so I'll answer your age out question first. Our age outs historically have been primarily distributor orders as compared to direct orders. With that said the comments I made about expecting age outs in '17 to improve as a percentage of backlog over fiscal 2016's level of 13% takes into account the increase in the revenue conversion cycle that both Josh and I highlighted. So we've already factored in any impact that would have in our age out guidance. 
Your first question with regards to differences in conversion timing, I mean the fact is it does vary by region. And you're going to see some differences. I think in this quarter we are impacted primarily, as I mentioned on the revenue side by our distributors in the European region primarily the non-Western European regions where we use distributors. However on a positive note, we highlighted I think in our third quarter call last year, Japan which is a region where we are 100% distributor and we've actually seen that conversion process improve over the last six to nine months, so much so that Japan now in the first half of 2017 is representing approximately 15% of total company revenues as compared to 5% in the first half of 2016. 

So it's vary region specific, macro factor specific, but the weakness and the delays we saw in the first half of 2017 were primarily Europe.
Anthony Petrone
Very helpful. Thanks. 
Operator
And our next question comes from Tycho Peterson from JPMorgan. Your line is open.
Unidentified Analyst
Hey guys, thanks. It's actually Patrick in for Tycho. Maybe just to expand on Anthony's question on revenue conversion. Definitely understand it's more difficult to handicap given distributors, all that direct control. But now that you've kind of identified that as a problem and increased focus on it, is there anything you can do to accelerate conversion from the distributors or how you're thinking about improving that a little bit. 
Joshua H. Levine
Yeah, so Patrick, it's a great question. We just as a little bit of background on the resources that we usually have involved, when we're involved in a direct sale and then where we have primary responsibility for installation. We've got installation teams and essentially revenue conversion teams in our regions that are working with end user facilities on site planning elements and site planning details, working on installation details and bunker modification components -- elements of the process, and coordination quite frankly in some cases with contractors locally to support those activities that I just described. Those resources are our resources that are dedicated and they‚Äôre focused by region and when we're direct sales mechanism and we‚Äôve got responsibility for installation, those resources are highly engaged, actively engaged in a really end-to-end process with the site and institution, the end user institution.
We are trying to work more closely with distributors to find out its ‚Äì it‚Äôs really a little bit of the help us, help you discussion. We‚Äôre working with them to find out what we can bring with regards to some of the resources I just described that would help augment or help support, perhaps in ways that they‚Äôre not capable of on their own, those ‚Äì the execution if you will of those activities that I just described. 
So we‚Äôve got a large number of independent distributors that we work with in different parts of the world, but this is not necessarily an exercise for us where we‚Äôve got to support every one of them. These -- the orders are probably, more heavily concentrated in, again, as Kevin described before, central Europe, certainly, as of ‚Äì most recently Japan -- well that‚Äôs an improving situation as Kevin highlighted. So we have -- I think we have the resources from the Accuray side that need to be engaged in these conversations with distributors pushing and expanding their involvement perhaps if you will in efforts to move this process forward in a more expedited fashion.
Unidentified Analyst
Okay. That‚Äôs helpful. And then may be one for Kevin, just on gross margins, now they‚Äôre obviously a bit soft in the first half. Now looking out -- you guys gave at the Analyst Day the longer term target of 45%. Maybe just talk to your confidence level in that number and the key leverage to get you there from obviously a lower base coming off first half of the year?
Kevin Waters
Yeah. So as I mentioned your question really is two parts. On the second quarter as I said, the most significant factor continues to be really mix and we were hurt in the first half of the year by product mix having a high ratio of Tomo revenues and also just an overall lower sales volume. We still think given our forecast for the back half for the year, we can get back to essentially flat product margins in 2017 as compared to 2016. 
Longer term, we still continue to work towards the goal we put forward on Analyst Day of 45% overall margins. This would represent service margins in the low 40% range, product margins in the high 40s. Revenue improvements are an obvious factor in regard to margin improvements, but another thing, we are also working on as a company, which we haven‚Äôt talked about in a few quarters, we do remain focused on cost down initiatives on our systems and we are currently investing in several large standing engineering products, which will not benefit fiscal 2017, but it is going to contribute as we head into 2018 and 2019.

So I don‚Äôt view our overall margin results in the first six months as any risk or indication that we can‚Äôt get to where we want to get to in fiscal 2019.
Unidentified Analyst
Understood. And maybe just one, last one, you guys mentioned Japan, an increase in product revenue, I don‚Äôt think you‚Äôve shown any improvement to Radixact yet. So maybe what are you anticipating that, what‚Äôs the visibility there on that, and then how significant is the opportunity for Radixact? Thank you.
Kevin Waters
Yes. So we‚Äôve submitted all the necessary paper work for showing [ph] an approval in Japan and we expect that very shortly, we expect in our fiscal third quarter.
Operator
[Operator Instructions] And our next question comes from Brandon Henry from RBC Capital Markets. Your line is open.
Brandon Henry
Yeah. Thanks for taking my question. Motion management, it's an important differentiator for CyberKnife, that‚Äôs not yet available on the Radixact platform. So can you provide us with an update on the timeline for the motion management for Radixact? And then discuss, how important you think this technology will be in driving TomoTherapy replacements? And I have a follow-up question.
Kevin Waters
Brandon, it‚Äôs a great question. The ‚Äì what you describe in terms of capability on CyberKnife, which is the motion management capability the software component to that which is the automated theme adjustment capability through synchrony, these are similar technology upgrades that we believe are going to be really pretty central to longer term adoption and utility of Radixact going forward.
This is a highly upgradable platform that will allow for motion tracking overtime, motion correction in terms of beam [ph] correction overtime. So, if you think about how CyberKnife has evolved Radixact would look again different platform obviously but would look similar in terms of how it tracts along those upgradability pathways if you will, and this is a major, at least my feedback, this is a major part of the thought process for those customers that are looking at considering Radixact in the replacement sales discussion. 
Again if you think it about it in terms of our existing installed base we‚Äôre taking a customer with earlier generation product and even in an upgraded form that earlier generation product will never get to the level of capability from a functionality perspective that Radixact will, given the functionality improvements that I just described. And we haven't been specifically quite frankly about timing, but I would say that we feel pretty good about the rate at which or the pace at which we are moving through our technology roadmap and advancing the development of these incremental product capabilities.
Brandon Henry
Okay. And then just a couple of questions. First, have you seen any differences in the historical win rate for replacements for TomoTherapy versus CyberKnife and then also the replacement rates for the U.S. versus international market?
Joshua H. Levine
No, we haven‚Äôt. I think the answer would be it's too early to draw any definitive conclusions. We‚Äôre very early in this replacement cycle. I will say the first half of 2017 yielded positive results on both product platforms. We saw in the U.S. predominantly all replacement sales and also predominantly CyberKnife related, while in the OUS we saw a nice mix of replacement sales and the competitive wins across both platforms. So I don‚Äôt think -- I think it‚Äôs too early in the cycle Brandon to draw any conclusion. We‚Äôre performing kind of at or above our expectations on replacements sales across both product platforms at the movement.
Brandon Henry
Okay. And then final question from me, you mentioned that operating expenses will now be down 3% to 4% for this fiscal year versus I think previous guidance, of kind of flat, can you talk about where the cost reduction is coming from and also if fiscal second half revenue performance does fall short of expectations, are there additional opportunities for cost cutting that would still allow you to meet your fiscal year 2017 adjusted EBITDA guidance? Thanks.

Kevin Waters
Yeah, I believe so. So we finished for the first six months of 2017 roughly down $10 million in OpEx or 12% below prior year. 4.4, roughly 4.5 of that is attributable to legal expenses, I'll call them nonrecurring and what you seeing in the first half is lower revenue levels leaving to decreased compensation expenses and decreased commission expenses. And our guidance right now of operating expenses down 3% assumes we're within our revenue range of $410 to $420 million and if we would be below that range I think it‚Äôs fair to suggest that our operating expenses could potentially be down less than 3% primarily due to the two factors on compensation that I just mentioned, which, by the way, in my prepared remarks I had said that's what gives us, I‚Äôd say particularly higher level of confidence in our ability to achieve our EBITDA range.
Brandon Henry
Okay. Thank you.
Kevin Waters
No problem.
Operator
And at this time, I‚Äôm showing no further questions. I would like to turn the call back to management for any closing remarks.
Joshua H. Levine
Thank you, operator. And thank you everyone for your participation on this afternoon‚Äôs call. We look forward to talking with you again on our fiscal third quarter earnings call and thanks and have a good evening.
Operator
Ladies and gentlemen, thank you for participating in today‚Äôs conference. This concludes the program and you may now disconnect. Everyone have a great day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!
About this article:ExpandTagged: Healthcare, Medical Appliances & Equipment, TranscriptsError in this transcript? Let us know.Contact us to add your company to our coverage or use transcripts in your business.Learn more about Seeking Alpha transcripts here.Follow SA Transcripts and get email alertsSearch TranscriptThis transcriptFindAll transcriptsFindCompare To:All ARAY TranscriptsOther Companies in this sector





Healthcare and Biotech Stocks | Seeking AlphaSign in / Join NowGO¬ªHealthcare and Biotech StocksIronwood Will Press On In The Good Fight Against GERDIRWD‚Ä¢ Yesterday, 5:26 PM ‚Ä¢ Long Term BioMannKind: Afrezza Scripts Stable At A Bit Above 300 - Will Ads Help?MNKD‚Ä¢ Yesterday, 4:15 PM ‚Ä¢ Spencer Osborne‚Ä¢17¬†CommentsIgnyta Lights The FireRXDX‚Ä¢ Yesterday, 3:28 PM ‚Ä¢ Strong Bio‚Ä¢1¬†CommentWhy Ironwood's IW-3718 Is 'Refluxing' Into A Sea Of RedIRWD‚Ä¢ Yesterday, 2:32 PM ‚Ä¢ Life Sciences Millennial‚Ä¢7¬†CommentsNovartis's Q2 Results: Encouraging Signals Fully Reflected In ValuationNVS‚Ä¢ Yesterday, 2:17 PM ‚Ä¢ HealthBlogger2 Small Oncology Stocks That Could Rally Through Year-EndRXDX, TGTX‚Ä¢ Yesterday, 1:23 PM ‚Ä¢ Bret Jensen‚Ä¢9¬†CommentsROTY Edition 1 Volume 14: Updates And A Ninth PositionCBAY‚Ä¢ Yesterday, 1:14 PM ‚Ä¢ Jonathan Faison‚Ä¢2¬†CommentsTrevena (TRVN) Investor Presentation - SlideshowTRVN‚Ä¢ Yesterday, 1:09 PM ‚Ä¢ SA TranscriptsJohnson & Johnson Is A Defensive Stock And Should Be In All Portfolios, Income Or GrowthJNJ‚Ä¢ Yesterday, 12:17 PM ‚Ä¢ William Stamm‚Ä¢13¬†CommentsTesaro's Stock Dip Is Nothing To Be Afraid OfTSRO‚Ä¢ Yesterday, 12:03 PM ‚Ä¢ Kevin McAdamsUnited Therapeutics Losing The Crown Jewels; 20% EPS Downgrades AheadUTHR‚Ä¢ Yesterday, 10:32 AM ‚Ä¢ World's Greatest‚Ä¢8¬†CommentsAn Endocrinologist Explains Her View Of Tymlos And The Osteoporosis LandscapeRDUS‚Ä¢ Yesterday, 10:20 AM ‚Ä¢ Slingshot Insights‚Ä¢2¬†CommentsSirukumab's Panel And U.S. Decision For Medicines CompanyMDCO, JNJ, GSK‚Ä¢ Yesterday, 10:18 AM ‚Ä¢ EP Vantage‚Ä¢1¬†CommentAchaogen EscalatesAKAO‚Ä¢ Yesterday, 10:03 AM ‚Ä¢ Strong Bio‚Ä¢4¬†CommentsMedtronic's Diabetes Segment Generating ExcitementMDT‚Ä¢ Yesterday, 8:37 AM ‚Ä¢ The Non-Consensus‚Ä¢5¬†CommentsGilead Has Another Ace Up Its SleeveGILD‚Ä¢ Thu, Jul. 20, 5:22 PM ‚Ä¢ Long Term Bio‚Ä¢51¬†CommentsMedtronic: A Dividend Aristocrat With Double-Digit Payout Growth PotentialMDT‚Ä¢ Thu, Jul. 20, 5:19 PM ‚Ä¢ Simply Safe Dividends‚Ä¢15¬†CommentsMannKind: Afrezza Television Ad Debuts; What Investors Need To KnowMNKD‚Ä¢ Thu, Jul. 20, 5:02 PM ‚Ä¢ Spencer Osborne‚Ä¢95¬†CommentsProtalix Is Undervalued With Upcoming CatalystsPLX‚Ä¢ Thu, Jul. 20, 4:50 PM ‚Ä¢ Jesse Donovan‚Ä¢42¬†CommentsTitan Pharmaceuticals: Just Be PatientTTNP‚Ä¢ Thu, Jul. 20, 4:30 PM ‚Ä¢ Matthew Burdeshaw‚Ä¢10¬†CommentsQuidel To Acquire Triage Assets From Alere DivestitureQDEL‚Ä¢ Thu, Jul. 20, 3:34 PM ‚Ä¢ Donovan JonesCymaBay Therapeutics' Strong Cash Raise Points To Near-Term UpsideCBAY‚Ä¢ Thu, Jul. 20, 2:56 PM ‚Ä¢ Jonathan Faison‚Ä¢5¬†CommentsVivus Settlement Could Clue In Orexigen InvestorsOREX, VVUS‚Ä¢ Thu, Jul. 20, 2:41 PM ‚Ä¢ Spencer OsborneIronwood Pharmaceuticals (IRWD) IW-3718 Phase IIb Clinical Trial Results - SlideshowIRWD‚Ä¢ Thu, Jul. 20, 1:59 PM ‚Ä¢ SA TranscriptsAerie Pharmaceuticals (AERI) Roclatan Mercury 1 Phase 3 12-month Topline Results - SlideshowAERI‚Ä¢ Thu, Jul. 20, 1:56 PM ‚Ä¢ SA TranscriptsIs The FDA Biotech's Best Friend?BDSI, ENDP, FOLD‚Ä¢ Thu, Jul. 20, 9:54 AM ‚Ä¢ Bret Jensen‚Ä¢24¬†CommentsViewRay: Initiate Strong Sell On Questionable Backlog, Product Inferiority, And Bankruptcy ConcernsEditors' Pick ‚Ä¢ VRAY‚Ä¢ Thu, Jul. 20, 9:45 AM ‚Ä¢ Mako Research‚Ä¢35¬†Comments3 Things In Biotech You Should Learn Today: July 20, 2017AMGN, RDHL, VRTX‚Ä¢ Thu, Jul. 20, 9:00 AM ‚Ä¢ Zach Hartman, PhD‚Ä¢5¬†CommentsFonar's medical diagnostic centers are delivering great returnsFONR‚Ä¢ Thu, Jul. 20, 8:43 AM ‚Ä¢ Blue Tower Asset Management, LLC‚Ä¢4¬†CommentsRaise After Raise: Sarepta Shares Are Still A BuySRPT‚Ä¢ Thu, Jul. 20, 6:08 AM ‚Ä¢ Jonathan Faison‚Ä¢15¬†CommentsBecton, Dickinson In The Garden PortfolioBDX‚Ä¢ Thu, Jul. 20, 6:03 AM ‚Ä¢ DJ Habig‚Ä¢9¬†CommentsSpark Therapeutics: Let The PDUFA Run-Up CommenceONCE‚Ä¢ Thu, Jul. 20, 12:06 AM ‚Ä¢ Jonathan Faison‚Ä¢3¬†CommentsNovartis Will Hit $100 This YearNVS‚Ä¢ Wed, Jul. 19, 8:40 PM ‚Ä¢ Individual Trader‚Ä¢9¬†CommentsAimmune Banks On Food Allergies, Study Expected To Show Positive ResultsAIMT‚Ä¢ Wed, Jul. 19, 5:06 PM ‚Ä¢ Emerging EquitiesJohnson & Johnson's Weakness Worries MeJNJ‚Ä¢ Wed, Jul. 19, 5:05 PM ‚Ä¢ Josh Arnold‚Ä¢12¬†CommentsUpcoming Soliris Catalyst Offers Hope For Battered Alexion StockALXN‚Ä¢ Wed, Jul. 19, 4:59 PM ‚Ä¢ Emerging Equities‚Ä¢4¬†CommentsGilead Sciences' Shares Just Answered The QuestionGILD‚Ä¢ Wed, Jul. 19, 4:34 PM ‚Ä¢ James Brumley‚Ä¢60¬†CommentsAt a 52 Week High, Can United Health Group Go Higher?UNH‚Ä¢ Wed, Jul. 19, 4:21 PM ‚Ä¢ Jeremy LaKosh‚Ä¢8¬†CommentsInnovation Pharmaceuticals Stock May Be A Triple-Crown Winner With Brilacidin By Year EndIPIX‚Ä¢ Wed, Jul. 19, 3:14 PM ‚Ä¢ KarinCA‚Ä¢55¬†CommentsJohnson & Johnson: This Market Will Buy AnythingJNJ‚Ä¢ Wed, Jul. 19, 3:01 PM ‚Ä¢ Stone Fox Capital‚Ä¢33¬†CommentsAddus HomeCare: Weathering The Health Care MaelstromADUS‚Ä¢ Wed, Jul. 19, 2:49 PM ‚Ä¢ Underanalyzed EquitiesAn Irrational Reaction To TherapeuticsMD's News ReleaseTXMD‚Ä¢ Wed, Jul. 19, 2:46 PM ‚Ä¢ Zheng Feng Chee‚Ä¢28¬†CommentsVertex Eyes The Treble In Cystic FibrosisVRTX‚Ä¢ Wed, Jul. 19, 2:27 PM ‚Ä¢ EP Vantage‚Ä¢3¬†CommentsFDA's Flashing Green Light Boosts Novel Drug ApprovalsGILD, PBYI, AZN‚Ä¢ Wed, Jul. 19, 2:09 PM ‚Ä¢ EP Vantage‚Ä¢3¬†CommentsCempra: Are We There Yet?Editors' Pick ‚Ä¢ CEMP‚Ä¢ Wed, Jul. 19, 1:57 PM ‚Ä¢ StrategyDoc‚Ä¢78¬†CommentsImmunogen Finally Moving 'FORWARD'?IMGN‚Ä¢ Wed, Jul. 19, 1:51 PM ‚Ä¢ Strong Bio‚Ä¢1¬†CommentVertex Pharmaceuticals (VRTX) Phase 1 And 2 Data For Triple Combination Regimens Demonstrate Improvements In Lung Function And Other Measures In CF PaVRTX‚Ä¢ Wed, Jul. 19, 1:30 PM ‚Ä¢ SA TranscriptsJ&J: Some Good News, But Here's Why It's Dropped A Level Or TwoJNJ‚Ä¢ Wed, Jul. 19, 12:56 PM ‚Ä¢ DoctoRx‚Ä¢51¬†CommentsCymaBay Phase 2 Liver Data Is A Great Buy OpportunityCBAY‚Ä¢ Wed, Jul. 19, 11:53 AM ‚Ä¢ Long Term Bio‚Ä¢4¬†CommentsROTY Edition 1 Volume 13: Updates And A Regulatory Runup PlayALBO, ZGNX, STDY‚Ä¢ Wed, Jul. 19, 11:01 AM ‚Ä¢ Jonathan Faison‚Ä¢4¬†CommentsPuma Wins FDA Approval: New Hope For HER2-Positive Breast Cancer PatientsPBYI‚Ä¢ Wed, Jul. 19, 10:35 AM ‚Ä¢ Long Term Bio‚Ä¢1¬†CommentBeiGene: This China-Based Biotech Continues To SurpriseBGNE‚Ä¢ Wed, Jul. 19, 9:53 AM ‚Ä¢ Jonathan Faison‚Ä¢5¬†CommentsInsmed (INSM) Investor Presentation - SlideshowINSM‚Ä¢ Wed, Jul. 19, 9:24 AM ‚Ä¢ SA TranscriptsRisk-Adjusted Net Present Value For Arbutus BiopharmaABUS‚Ä¢ Wed, Jul. 19, 8:45 AM ‚Ä¢ Oscar CarrascosaGilead At 30: Re-Entry TimeGILD‚Ä¢ Wed, Jul. 19, 8:34 AM ‚Ä¢ Out of Ignorance‚Ä¢60¬†CommentsValeant Pharmaceuticals: Becoming A Better Buy?VRX‚Ä¢ Wed, Jul. 19, 8:28 AM ‚Ä¢ Orthodox Investor‚Ä¢71¬†CommentsVertex Pharmaceuticals Looks To Push The EnvelopeVRTX‚Ä¢ Wed, Jul. 19, 6:14 AM ‚Ä¢ Long Term Bio‚Ä¢5¬†CommentsCalyxt Inc.: Regulatory Hurdles Keep Us Cautious On This (Otherwise Exciting) IPOCLXT‚Ä¢ Wed, Jul. 19, 2:29 AM ‚Ä¢ Don Dion‚Ä¢3¬†CommentsKala Pharmaceuticals Looks Promising Ahead Of IPOKALA‚Ä¢ Tue, Jul. 18, 9:25 PM ‚Ä¢ Don Dion‚Ä¢6¬†CommentsChaos At AstraZenecaAZN‚Ä¢ Tue, Jul. 18, 7:23 PM ‚Ä¢ Derek Lowe‚Ä¢12¬†CommentsMallinckrodt: A Crowded Short Where The Bear Thesis Is Falling ApartMNK‚Ä¢ Tue, Jul. 18, 7:18 PM ‚Ä¢ One Other Fool‚Ä¢28¬†CommentsTake Profits On GileadGILD‚Ä¢ Tue, Jul. 18, 3:52 PM ‚Ä¢ Giovanni DiMauro‚Ä¢82¬†CommentsHerbalife: A Viable ShortHLF‚Ä¢ Tue, Jul. 18, 3:08 PM ‚Ä¢ Brian Sanders‚Ä¢123¬†CommentsWhy Keeping Up With FDA Approvals Could Help Your Stock Portfolio - Slingshot Insights' Joe McCann's Idea Of The MonthEditors' Pick ‚Ä¢ RDUS‚Ä¢ Tue, Jul. 18, 2:55 PM ‚Ä¢ Slingshot Insights‚Ä¢2¬†CommentsNektar Therapeutics (NKTR) Updates On Topline Results of Oral Human Abuse Potential (NKTR-181) - SlideshowNKTR‚Ä¢ Tue, Jul. 18, 2:38 PM ‚Ä¢ SA Transcripts‚Ä¢1¬†CommentQuidel (QDEL) Updates On Acquisition Of Alere's Triage (ALR) Assets - SlideshowQDEL, ALR‚Ä¢ Tue, Jul. 18, 2:26 PM ‚Ä¢ SA TranscriptsCymabay Therapeutics (CBAY) Seladelpar Phase 2 Low Dose Study In PBC - SlideshowCBAY‚Ä¢ Tue, Jul. 18, 2:13 PM ‚Ä¢ SA TranscriptsInvestors Waiting In BioLineRxBLRX‚Ä¢ Tue, Jul. 18, 1:58 PM ‚Ä¢ Strong Bio‚Ä¢5¬†CommentsNovartis AG 2017 Q2 - Results - Earnings Call SlidesNVS‚Ä¢ Tue, Jul. 18, 1:57 PM ‚Ä¢ SA TranscriptsJohnson & Johnson Is DeliveringJNJ‚Ä¢ Tue, Jul. 18, 1:52 PM ‚Ä¢ Quad 7 Capital‚Ä¢13¬†CommentsEiger Biopharmaceuticals: Can This $10 Biotech Stock Continue To Rally?EIGR‚Ä¢ Tue, Jul. 18, 1:30 PM ‚Ä¢ Bret Jensen‚Ä¢2¬†CommentsBiotech Forum Daily Digest: Update On Approximately $5 CytosorbentsCRSP, CTSO, EDIT‚Ä¢ Tue, Jul. 18, 11:58 AM ‚Ä¢ Bret Jensen‚Ä¢5¬†CommentsAmgen Receives CRL For Osteoporosis Drug: What's The Next Step?AMGN‚Ä¢ Tue, Jul. 18, 11:55 AM ‚Ä¢ Long Term Bio‚Ä¢9¬†CommentsHTG Molecular Diagnostics Has Its Own NicheHTGM‚Ä¢ Tue, Jul. 18, 11:33 AM ‚Ä¢ Thomas Pangia‚Ä¢6¬†CommentsUnited Therapeutics: Shareholders Profitably UnitedUTHR‚Ä¢ Tue, Jul. 18, 10:50 AM ‚Ä¢ Strong Bio‚Ä¢4¬†Comments123456...467Next Page









Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #472610c0-6e9c-11e7-b15d-39258c18c06c
          





            Powered by
            PerimeterX
            , Inc.
          













Josh Levine's profile on Product Hunt




























Product HuntThe best new products, every dayAsk‚óè|Log InSign up¬†MJosh Levine#415580@josh_levinehttp://josh.com0Following0FollowersFollow2 UpvotesEvaThe distraction-free couples‚Äô vibeTech+ 2¬†save¬†50¬†3trumpWAPtrumpWAP makes the web great again by adding more trump.Productivity+ 2¬†save¬†4¬†1Share this profileRecent RecommendationsWhat are must-have Chrome Extensions?What are must-have Chrome Extensions?What are must-have Chrome Extensions?What are must-have Chrome Extensions?Recent CommentsMake Twitter Great AgainMake Twitter Great AgainOneTabtrumpWAP






 


Joshua Levine
 | LinkedIn
 


























 









LinkedIn



















































Main content starts below.




Joshua LevineAccount Manager - Inside Sales / Visual Communications Specialist at FASTSIGNS¬Æ Orlando, FL - CentralLocationOrlando, FloridaIndustryPrintingCurrentFASTSIGNS¬Æ Orlando, FL - Central, Professional Fine ArtistPreviousSeveral Companies, IsramWorld, Capricorn LeisureEducationUniversity at BuffaloRecommendations3 people have recommended JoshuaWebsitesCompany Website500+ connectionsView Joshua‚Äôs full profile. It's¬†free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View Joshua‚Äôs Full ProfileJoshua‚Äôs Posts & ActivityNOW HIRING GRAPHIC DESIGNER -...Joshua Levine on LinkedInDecember 19, 2016See 12 more postsNOW HIRING GRAPHIC DESIGNER - FASTSIGNS OrlandoJoshua sharedCute !!Joshua likedPhotoJoshua likedSee all activityExperienceAccount Manager - Inside Sales / Visual Communications SpecialistFASTSIGNS¬Æ Orlando, FL - CentralJune 2016  ‚Äì  Present (1 year 2 months)FASTSIGNS¬Æ Orlando Central¬†is an Award Winning Center, providing¬†signage, graphics and visual communications¬†solutions to help customers of all sizes, across all industries,meet their business objectives. By partnering with our clients we increase the visibility of their business or organization through the use of signs, graphics, printing, promotional products and related marketing services. By utilizing a consultative sales approach, I make recommendations to prospects and clients using  FASTSIGNS productsI Develop and maintain a database of qualified leads using proven sales strategies/techniques, build and foster relationships with a network of referrals in the local community to create new opportunities for revenue growth.Manage multiple projects simultaneously across multiple clients to ensure timely and quality service and completion of all assignments.I maintain accurate documentation for sales and prospecting activities and provide status reports, complete all required client/project paperwork and ensure complete customer satisfaction..ArtistProfessional Fine ArtistOctober 2011  ‚Äì  Present (5 years 10 months)Orlando, Florida AreaCreative artistExhibited at CityArts Factory, Orlando Customer Service / Telemarketing Sales RepresentativeSeveral CompaniesJanuary 2013  ‚Äì  May 2016 (3 years 5 months)As a professional artist; I concentrated on my art-work while working in various part-time customer service and telemarketing positions.  Sales / Operations SupervisorIsramWorldNovember 2004  ‚Äì  October 2011 (7 years)Assisted the Chief Operating Officer and the VP of Operations/Reservations in overall management of Mediterranean / Middle East division of large tour operator. Supervised staff of 14 in all aspects of reservations sales, customer service and operations. Responsible for hotel contracting and tour package pricing, itinerary development, brochure creation, staff training and quality control.  Ensured efficient flow of work from initial reservation thru preparation of final travel documents.Sales RepCapricorn LeisureMarch 2003  ‚Äì  November 2004 (1 year 9 months)Designed and sold both bulk vacation packages and customized travel itineraries to destinations throughout Central America. Heavy client and supplier contact.  Represented company at trade shows and Industry conferences.Operations ManagerSceptre ToursMarch 1998  ‚Äì  March 2003 (5 years 1 month)Oversaw growth from an air only charter operator with 20,000 passengers a year to an air and land tour operator with over 70,000 passengers a year on scheduled airlines. Coordinated startup of tour program including setting up operations systems, negotiating rates, and allotments, product planning, data loading and yield management. Worked closely with Reservations Manager in training staff on product knowledge and sales procedures.Travel Management Consultant - Self EmployedSelf-EmployedJanuary 1997  ‚Äì  March 1998 (1 year 3 months)Assisted owners of several travel companies as a management consultant on a temporary assignment basis. Developed various tour programs for sale and implemented operational systems. Negotiated with air and land suppliers for rates and allotments. Handled itinerary planning, product costing, database setup and staff training.Product / Database ManagerInter-Island ToursNovember 1995  ‚Äì  January 1997 (1 year 3 months)Responsible for negotiating and coordinating hotel and airline contracts, inventory and database for Caribbean tour operator. Oversaw a major expansion of the product line, from 8 destinations with 100 hotels growing to 12 destinations and over 200 hotels. Functioned as liaison between operations, sales and reservations departments.Reservations Sales / Operations ManagerSunburst HolidaysApril 1991  ‚Äì  November 1995 (4 years 8 months)Managed staff of 20 reservations sales agents and operations personnel for Caribbean charter tour operator. Negotiated contracts and room allotments with General Managers and Sales Managers at over 100 hotel suppliers to ensure competitive pricing. Responsible for database maintenance, yield management, allotment control, ticketing and staff development.ManagerAOT ToursJuly 1988  ‚Äì  April 1991 (2 years 10 months)In charge of both operations and database administration departments for Caribbean and North American tour operator. Maintained inventory control on over 400 hotel properties. Managed staff of 7 with full responsibility for contract coordination, product planning and database loading,air and hotel reservations and transfers.ManagerGlobus Gateway / CosmosFebruary 1983  ‚Äì  July 1988 (5 years 6 months)Rose through company from Reservations Agent to Airline Sales Administrator to Reservations Supervisor, responsible for a staff of 40 sales agents. Initiated use of airline CRS / GDS systems for tour sales. Promoted to Operations Manager, N. America, in charge of itinerary planning, costing, tour directors and supplier relations.SummaryAs a professional artist; for the past few years I have been on a "sabbatical"; concentrating on my art-work and have now returned to fulltime sales position with FastSigns.SkillsPrinting SolutionsCustomer ServiceTelemarketingSalesSalesforce.comMicrosoft ExcelMeeting PlanningTrade ShowsCorporate EventsTravel ManagementHotelsVacationTravel PlanningHotel BookingLeisure TravelSee 34+HospitalityLeisureTour OperatorsBooking SystemsTourismTrainingFront OfficeBusiness TravelEvent ManagementCruisesIncentivesResortsAirlinesTicketingAdventure TravelLuxuryOnline TravelHospitality IndustryDisneyIncentive TravelLeadershipOnline MarketingManagementDestination MarketingAmadeusTour ManagementYield ManagementRevenue AnalysisGuided ToursTravel WritingCar RentalGoogle GroupsNegotiationHotel ManagementSee lessHow's this translation?Great‚Ä¢Has errorsThanks for your help!EducationUniversity at BuffaloCommunication / Public RelationsCommunication / Public Relations1977  ‚Äì  1981High School of Art & Design  NYCRegents Diploma, Graphic DesignRegents Diploma, Graphic Design1972  ‚Äì  1975Activities and Societies: Founding co-Editor of A&D Palette, the school newspaperVolunteer Experience & CausesCauses Joshua cares about:Animal WelfareArts and CultureCivil Rights and Social ActionEducationEnvironmentHuman RightsPoliticsRecommendationsA preview of what LinkedIn members have to say about Joshua:Joshua was very knowledgeable of all the brochures products that ISRAM offered.  He is detailed oriented and he was the first I used to approach if I had questions regarding tours, hotels and any other item in our brochure.
Joshua has a good sense of humor and strong work ethics.See moreSee lessJoshua was a winderful and knowledgable supervisor who took the extra time to provide the best customer service.See moreSee lessSign up to see who recommended JoshuaGroupsMarketing CommunicationTravel and Tour WorldWorld Tourism NetworkOperations ManagerTHAT's Professional (Travel, Hospitality, Aviation & Tourism)Start Up JOBS in IsraelOnline Travel TechnologySee 7 moreStrategic Alliance OrlandoHotel Contracting & Negotiations ~ Intelligence & StrategiesOrlando Entrepreneur NetworkTravel, Tourism & Hospitality GroupFlorida Special Events NetworkNetworking OrlandoTour Operator / Travel AgentSee lessView Joshua‚Äôs full profile to...See who you know in commonGet introducedContact Joshua directlyView Joshua‚Äôs Full ProfileNot the Joshua you‚Äôre looking for? View moreView this profile in another languageEnglishChinese (Simplified)GermanPeople Also ViewedLuigi GarzilloManaging DirectorRuben Sederman Compass Travel Israel*Israel Daily Group Tours *Private Tours* Israel Tour Packages*Israel Pilgrimage Tours*Transportion Rental*Israeli VisaJeannine LitmanowiczGM at Macedonian, Serbian, Albanian Tourism Expert - Be My Guest in the BalkansLinoy ReuveniLooking for my next opportunityRick Stoneking SrKlout Expert - Publishing Travel Tourism Hospitality Copywriting Content Marketing
Social Media Terrorism  AccessibilityLarry BashamChief Operating Officer at Elite Island ResortsLeia TaggartSr. Travel Consultant at Direct Travel Zvi HarpazGeneral Manager / Tour Guide at Zvi Harpaz - Guided ToursDarya CamacciIka ChipmanSocial Tourism MarketingPublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesFind a different Joshua LevineFirst NameLast NameExample:  Joshua LevineJoshua LevineJewish community developmentIsraelJosh LevineCEO at XTL BiopharmaceuticalsIsraelJosh LevineYoga InstructorIsraelJosh LevineHealth, Wellness and Fitness ProfessionalIsraelMore professionals named Joshua LevineLinkedIn members in Israel:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country























Joshua L Levine - New York, NY | Intelius



























Sign In



We found Joshua L Levine in New York, NY


Joshua L Levine

                                                                           Intelius found that Joshua L Levine  is  a male between 50 and 60 years old from New York, NY.  We have connected them to
                11 addresses,
                8 phones,
                and 6 relatives or associates.
         





Also Known As

Joshua R Levine


Get Report Now

Age

Joshua L Levine is in his 50s

Joshua Has Lived In

New York, NY
New Orleans, LA
Bronx, NY

Joshua's Relatives

Andrew Levine
Benjamin Levine
Warren Levine
Judith Levine







Joshua L Levine



Zodiac SignSagittarius



GenderMale



Professional Status
Plastic Surgery at The New York Eye and Ear Infirmary



Get Report Now










Want to know more about Joshua? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Joshua, or use our people search engine to find others.
Get Background Check on Joshua L Levine
Get a Criminal Check on Joshua L Levine
Get a Public Record Report on Joshua L Levine
Get a People Search Report on Joshua L Levine


Joshua L Levine's Contact Information
Known Cities Lived In
Find out where Joshua L Levine has lived as well as Joshua L Levine's phone numbers and email addresses.




Joshua L Levine Has Lived in 5 States
New York Address for Joshua L Levine


545 W 1**** S* 

New York, NY


Has Lived In

New York, NY
New Orleans, LA


Get Full Address Report










Phone Numbers Associated with Joshua L Levine

() ***-**** - New York, NY 
(212) ***-**** - New York, NY 
(646) ***-**** - New York, NY 


Get Full Phone Report



Email Addresses Associated with Joshua L Levine

j*****e@***.edu


Get Email Report




Joshua L Levine's Professional Information
Information regarding Joshua L Levine's professional history.  Find out previous places Joshua L Levine has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Joshua L Levine Has Worked at 1 Place
Company: The New York Eye and Ear Infirmary
               Title: Plastic Surgery
Joshua L Levine's Experience
Title: Plastic Surgery
               Company: The New York Eye and Ear Infirmary
Job Details

Additional Professional Information on Joshua L Levine

 See Joshua L Levine's LinkedIn Profile



Joshua L Levine's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Joshua L Levine


Joshua L Levine's known Social Networks And Potential Email Matches

Find all of Joshua L Levine's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Joshua Levine
Username Matches

                  JoshuaLevine
                  LevineJoshua
                  Joshua.Levine
                  Levine.Joshua
                  Joshua_Levine
                  Levine_Joshua
                  Joshua-Levine
                  Levine-Joshua
                  JLevine
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
J Levine







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual‚Äôs eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About¬†Us
Site Map
About¬†Our¬†Reports
Blog
Help
Contact¬†Us

¬© 2003 ‚Äì 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy¬†Policy - UPDATED
Terms¬†of¬†Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.














Joshua Alexander Levine - San Jose, CA | Intelius



























Sign In



We found Joshua Alexander Levine in San Jose, CA


Joshua Alexander Levine

                                                                           Intelius found that Joshua Alexander Levine  is  a male between 30 and 40 years old from San Jose, CA.  We have connected them to
                11 addresses,
                5 phones,
                and 5 relatives or associates.
         





Also Known As

Josh  Levine


Get Report Now

Age

Joshua Alexander Levine is in his 30s

Joshua Has Lived In

San Jose, CA
Palo Alto, CA
Saratoga, CA

Joshua's Relatives

Christa Levine
Anne Levine
Peter Levine
Sara Levine







Joshua Alexander Levine



Zodiac SignGemini



GenderMale



Professional Status
Lighting Td at Weta Digital



Get Report Now










Want to know more about Joshua? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Joshua, or use our people search engine to find others.
Get Background Check on Joshua Alexander Levine
Get a Criminal Check on Joshua Alexander Levine
Get a Public Record Report on Joshua Alexander Levine
Get a People Search Report on Joshua Alexander Levine


Joshua Alexander Levine's Contact Information
Known Cities Lived In
Find out where Joshua Alexander Levine has lived as well as Joshua Alexander Levine's phone numbers and email addresses.




Joshua Alexander Levine Has Lived in 1 States
California Address for Joshua Alexander Levine


6930 G******** D* 

San Jose, CA


Has Lived In

San Jose, CA
Palo Alto, CA


Get Full Address Report










Phone Numbers Associated with Joshua Alexander Levine

(530) ***-****
(510) ***-**** - Palo Alto, CA 
(510) ***-**** - Berkeley, CA 


Get Full Phone Report



Email Addresses Associated with Joshua Alexander Levine

p******4@***.com
j***********e@***.com


Get Email Report




Joshua Alexander Levine's Education Information
Known Schools Attended
Learn about Joshua Alexander Levine's academic history.  Find out which schools Joshua Alexander Levine attended, the dates attended as well as the degrees Joshua Alexander Levine received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Joshua Alexander Levine Has Attended 2 Schools
Stanford University 1994 ‚Äì 1996               Joshua Alexander Levine has a Left W/o degree in Structural Biology               
University of California, Berkeley               1990 ‚Äì 1994                              


Joshua Alexander Levine's Professional Information
Information regarding Joshua Alexander Levine's professional history.  Find out previous places Joshua Alexander Levine has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Joshua Alexander Levine Has Worked at 6 Places
Company: Weta Digital
               Title: Lighting Td
Company: Industrial Light & Magic
               Title: Technical Director
Joshua Alexander Levine's Experience
Title: Lighting Td
               Company: Weta Digital
Job Details
               Privately Held; 501-1000 employees; Motion Pictures and Film industry
Title: Technical Director
               Company: Industrial Light & Magic
Job Details
               Privately Held; 1001-5000 employees; Entertainment industry
Additional Professional Information on Joshua Alexander Levine

 See Joshua Alexander Levine's LinkedIn Profile



Joshua Alexander Levine's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Joshua Alexander Levine


Joshua Alexander Levine's known Social Networks And Potential Email Matches

Find all of Joshua Alexander Levine's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Joshua Levine
Username Matches

                  JoshuaLevine
                  LevineJoshua
                  Joshua.Levine
                  Levine.Joshua
                  Joshua_Levine
                  Levine_Joshua
                  Joshua-Levine
                  Levine-Joshua
                  JLevine
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
J Levine







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual‚Äôs eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About¬†Us
Site Map
About¬†Our¬†Reports
Blog
Help
Contact¬†Us

¬© 2003 ‚Äì 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy¬†Policy - UPDATED
Terms¬†of¬†Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











Accuray's (ARAY) CEO Joshua Levine on Q3 2017 Results - Earnings Call Transcript | Seeking AlphaSign in / Join NowGO¬ªAccuray's (ARAY) CEO Joshua Levine on Q3 2017 Results - Earnings Call TranscriptApr.27.17 | About: Accuray Incorporated (ARAY) Accuray, Inc. (NASDAQ:ARAY)
Q3 2017 Earnings Conference Call
April 27, 2017, 16:30 ET
Executives
Joshua Levine - CEO, President and Director
Douglas Sherk - Founder and CEO, EVC Group Inc.
Kevin Waters - CFO and SVP
Analysts
Tycho Peterson - JPMorgan Chase & Co
Joshua Jennings - Cowen and Company
Brandon Henry - RBC Capital Markets
Christian Moore - Jefferies LLC
Ryan Zimmerman - BTIG
Operator
Welcome to the Accuray Incorporated Third Quarter Fiscal 2017 Earnings Conference Call. [Operator Instructions]. As a reminder, today's conference is being recorded. I'd now like to introduce your host for today's conference, Mr. Doug Sherk. Sir, please go ahead.
Douglas Sherk
Thank you, Liz and good afternoon, everyone. Welcome to Accuray's conference call to review financial results for the third quarter of fiscal 2017 which ended on March 31, 2017, as well as recent corporate developments. Joining us today are Josh Levine, Accuray's President and Chief Executive Officer; and Kevin Waters, Accuray's Senior Vice President and Chief Financial Officer.
Before we begin, I'd like to remind you that our call today includes forward-looking statements that involve risks and uncertainties, including statements regarding our business plans and strategies as well as our outlook for fiscal 2017.
There are a number of factors that could cause actual results to differ materially from our expectations including, but not limited to, risks associated with the adoption of the CyberKnife, TomoTherapy, Onrad and Radixact Systems; commercial execution; future order growth; future revenue growth; and macroeconomic factors outside of the company's control.
These and other risks are more fully described in the press release we issued after the market closed this afternoon as well as in our filings with the Securities and Exchange Commission. The forward-looking statements on this call are based on information available to us as of today's date and we assume no obligation to update any forward-looking statements. [Operator Instructions].
Now I'd like to turn the call over to Accuray's President and Chief Executive Officer, Josh Levine.
Joshua Levine
Thank you, Doug. Good afternoon, everyone and thank you for joining us on today's call. Following the market close today, we reported third quarter financial results highlighted by strong growth for both gross orders and backlog. Gross orders for the third quarter increased 49% year-over-year to $83.8 million while our backlog grew to a record $450 million which is approximately 21% higher than prior year. This built upon our second quarter gross order results that we reported in late January which were also ahead of our expectations. These order results help illustrate why we reiterated our gross order guidance for the full year back in January and are doing so again today.
At the same time, our revenue results in the third quarter were moderated by the continued delay in the announcement of class A radiotherapy licenses in China and the long revenue conversion time associated with a higher mix of distributor source orders. We have pointed out during our Q2 earnings call that our full year revenue outlook could potentially be impacted by these 2 factors and this was proven to be the case. As a result, we're recasting our full year revenue outlook to a range of $380 million to $390 million. While we're encouraged by our continued momentum in order growth, we're not pleased with the trends related to the timing of revenue conversion and are announcing today a number of executive-level personnel and structural organization changes with a focus in 3 key areas, first, to ensure that we build on our recent order momentum; second, to improve our revenue conversion time lines in those regions where distributor-initiated orders have become a bigger part of the overall order mix in our backlog; and lastly, to drive a more streamlined executive-level structure to improve our overall market responsiveness.

The first of these changes is the elimination of the Chief Operating Officer position held by Kelly Londy; and the promotion of Lionel Hadjadjeba, the Senior Vice President and Chief Commercial Officer. Kelly will remain with Accuray through the end of the fiscal year to ensure a smooth transition and I deeply appreciate her many contributions to Accuray over her 6-year tenure. At the same time, I look forward to working more directly with Lionel and his commercial management team to drive our business.
As Chief Commercial Officer, Lionel will bring a high level of focus, accountability and urgency to our commercial sales efforts. Additionally, in this role, Lionel will help bridge and link the multiple departments and personnel that are involved in customer-facing activities, some of which are regionally based and some of which come from our headquarter location in Sunnyvale and our international subsidiary location outside of Geneva, Switzerland. Lionel joined Accuray in 2012 as the president of our international business and most recently has been leading the worldwide sales and service organization. In this new role, Lionel will remain -- will maintain worldwide responsibility for all our sales regions while reporting directly to me. Lionel will lead all of the corporate and region-based customer-facing activities and processes that impact commercial momentum, including sales, marketing, service, medical affairs, training and medical education.
Additionally, we announced today the creation of a dedicated Vice President of Revenue Management position that will report to Kevin Waters, our Chief Financial Officer. This position will be responsible for driving the revenue forecast and overseeing the order-to-revenue conversion process for the company by working closely with our regional installation, service and commercial teams to ensure we will improve the overall timing and cadence of system installation and ultimately revenue conversion.
Turning back to the quarter's results. Our third quarter order results validate customer market perceptions about our improved product functionality, performance and reliability. Accuray's competitive position for both product and service offerings continues to strengthen. And on a global basis, we continue to win more competitive bunkers than we lose. In addition, our product portfolio is strongly aligned with 2 of the fastest-growing radiotherapy treatment segments, image-guided IMRT and SBRT.
The latest generation of our TomoTherapy product platform, Radixact, has continued to contribute to our order growth since the early rollout phase of reference sites began late last calendar year. I'm happy to announce we have completed the ramp in monitor phase of the commercial launch process. And as of today's call, full commercial launch is now underway. We have received positive feedback from all of our reference sites in the U.S. and Europe that confirm Radixact's improvements in treatment planning and overall treatment speed as the standout differentiating attributes of the system while still providing our customers with the unparalleled treatment precision of the TomoTherapy architecture for their most challenging cases.
As an example, we have received feedback from one of our reference sites at a new state-of-the-art cancer center in South Florida. This customer has routinely been treating over 30 patients per day within a standard daily treatment schedule. Customers at our other reference sites have shared similarly positive feedback. The Radixact System is proving itself to be a platform that can treat the broadest range of cancer patients quickly and precisely, making it a viable choice as a mainstream clinical treatment option.
In another positive piece of Radixact news, in January, we received Shonin approval in Japan for Radixact and we're able to secure several Radixact orders from that market during the fiscal third quarter which exceeded our expectations. Additionally, we expect our first Radixact patient treated in Japan sometime in fiscal Q4.

Accuray's second new product, Onrad, also provided a modest contribution to our fiscal Q3 gross orders which was in line with our expectations. And we're continuing to focus on advancing the provincial tender processes and building our sales funnel for this segment of the market. As we had communicated in our last call, we expected initial OnRad order uptake in Q3 with order momentum ramping from there.
Moving to CyberKnife. We saw continued market interest and order momentum during the third quarter. CyberKnife orders represented approximately 50% of our gross order dollars in the quarter. We believe much of this momentum can be attributed to the better clinician and patient experiences provided by the CyberKnife M6 system, including greater functionality with the MLC-enabling treatment of a broader case range with faster planning and treatment times. We also believe market awareness and confidence in CyberKnife's unique capabilities for treating prostate cancer which is the fastest-growing cancer diagnosis in the male population, is helping to drive prospective customer interest.
Recently emerging clinical data about CyberKnife's capabilities in the treatment of prostate cancer is having a positive effect on customer awareness. The most recent CyberKnife study was presented at the ASCO-sponsored Genitourinary Cancers Symposium by Dr. Donald Fuller in February. Dr. Fuller's study showed that CyberKnife treatment's for treating localized prostate cancer can be successfully delivered by community-based centers as well as academic hospitals. 90% of the 259 patients in the study were treated at facilities identifying themselves as community-based nonacademic across the United States. And after a 5-year follow-up, 100% of the 112 patients low-risk patients treated by CyberKnife remain disease-free and 88.5% of the intermediate-risk patients treated remain disease-free. Importantly, the study also found that toxicity levels in the 259 patients treated with CyberKnife compare favorably to the toxicity levels of other radiotherapies.
Dr. Fuller's results mirror the clinically significant CyberKnife-specific SBRT prostate study presented at ASTRO last September by Dr. Robert Meier. When taken together, the clinical findings of both of these important studies represent the first truly device-specific data with long term patient follow-up and validate CyberKnife's unique capabilities and clinical value for safely and effectively treating low- and intermediate-risk prostate patients. Clinical studies at the time led by Doctors Meier and Fuller help clinically validate and continue to drive the broader market trends we're seeing in the shift towards SBRT and hypofractionated treatment delivery. 
In another example of how CyberKnife is transforming prostate treatment delivery, feedback from one of the largest volume, multidisciplinary urology practices in the U.S. indicated that they had recently treated their 1,000th patient -- prostate patient with their MLC-equipped CyberKnife since installing the M6 system in October of 2013, with a significant ramp in the number of patients over the last 2 years. We believe the most recently released clinical data on the treatment of prostate cancer with CyberKnife can be particularly powerful in the upcoming months when CMS is expected to release a report on episodic payments. Both ASTRO and ACRO have submitted proposals to CMS on episodic payment models. These proposals if adopted would position hyperfractionation which is what our technologies are extremely well suited to provide, in favorable reimbursement position.
Additionally, the U.S. Preventative Services Task Force has issued draft screening guidelines for prostate cancer that, rather than discouraging screening, advised patients to discuss screening with their doctors. We anticipate finalization of those guidelines later this calendar year and believe they will be a positive catalyst that will likely bring patients in for earlier diagnosis and treatment.

Finally, I'd like to have a -- say a few words about customer feedback. At the beginning of this month, we held the Accuray AERO Users' Summit in Chicago. While this summit enables our customers to share best practices and learn about innovative approaches to improving treatment results for their patients, it also enables our management team to gather customer feedback. Over the course of the 2-day event, we met with more than 70 customers, representing a broad cross-section of large academic institutions as well as smaller regional and community-based facilities and received an overwhelming level of support and positive feedback for the improvements we have made to the functionality and reliability of our product portfolio.
We believe that the organizational changes we announced today will result in improved consistency and execution of both orders and revenue conversion timing. The growth drivers we have laid out for our business remain firmly in place, namely the growing need for radiotherapy devices globally, the positioning of Accuray's product portfolio in the fastest-growing treatment segments of the market, the growing body of data illustrating the clinical efficacy of Accuray's technology and the upcoming replacement sales opportunity in our installed base with systems entering their 10-year replacement window.
And with that, I'd like to turn the call over to Kevin.
Kevin Waters
Thank you, Josh and good afternoon, everyone. As Josh highlighted, we ended the third quarter with backlog of $450 million, representing growth of 21% over the prior year. Our Q3 performance included gross orders of $83.8 million and net orders of $71.8 million, reflecting age-outs of $8.5 million, 1 cancellation for $2.8 million and $700,000 of negative foreign currency impact. Age-outs in the quarter were better than we anticipated, as an order which we expected to age-out ended up being shipped during the quarter.
Gross order performance was favorably impacted by both our new Radixact System as well as significantly more CyberKnife System orders compared to the same prior year period.
Order growth by geography was driven by strong performance in Asia Pacific, Japan and our European region. On a year-to-date basis order growth is up 13% over the first 9 months of prior year. Additionally, our replacement order rates have continued at a consistent pace during the first 9 months of fiscal 2017.
Turning now to our income statement. Total revenue for the third quarter was $97.3 million, representing an increase of 11% on a sequential basis. This compares to revenue of $105.3 million in the year ago period.
Product revenue for the quarter was $48 million. Product revenues in both the U.S. and Japan were significantly above prior year revenues. However, as Josh touched on, both China and the longer revenue conversion times, particularly in Europe, negatively impacted Q3 revenue performance.
Service revenue for the third quarter was $49.3 million compared with $51.5 million in the year ago period which was slightly below our expectations due to less installation and training revenue which coincides with the shortfall in product revenues.
Turning now to gross margins. Our overall gross margin for the quarter was 36.4% compared with the prior year period gross margin of 42.7%, primarily driven by reduced product gross margins. Product gross margins decreased 650 basis points over the prior year, primarily driven by the lower overall unit sales volume as well as product and channel mix. Overall pricing was stable as compared to the year ago period and within our expectations.
Product gross margins should improve sequentially in the fourth quarter on higher unit sales volume. However, on a full year basis, product margins will now be approximately 37% to 39% which is due to a combination of product and channel mix and lower overall revenues.

Service gross margins in the fiscal third quarter were 34% as compared with 40% in the year ago period. On a year-to-date basis, service margins are 36% which are slightly below prior year-to-date performance of 37%. We continue our focus on improved parts reliability and cost management and continue to anticipate full year fiscal 2017 service margins to be at or above 2016 which were 36%.
Operating expenses for the quarter were $36.7 million. This 7% reduction compared to the prior year was driven by a $2.5 million decrease in G&A and an $800,000 decrease in R&D while we had a slight increase of $500,000 in selling and marketing.
Our improvement in G&A was the result of lower legal expenses while R&D was the result of lower development expenses, primarily related to prior year costs associated with the development of the Radixact System. Adjusted EBITDA was $7.1 million compared to $13.9 million in the year ago period. Adjusted EBITDA through the first 9 months of the fiscal year was $10.1 million compared to $19.6 million in the prior year.
Turning to the balance sheet. We had $84.1 million of cash and investments at March 31, 2017. The $24.3 million sequential decrease in cash from the second quarter is due to restricting $12.5 million to satisfy future payment obligations associated with our term loan and also a decrease from working capital usage.
With regard to our fourth quarter cash flows, we expect to generate positive cash flow, primarily through a decrease in working capital on reduced accounts receivable and inventory balances.
With respect to our outstanding convertible debt that is due in February 2018, we're currently evaluating all financing sources that will allow us to either refinance our existing convertible debt or provide the cash necessary to settle the debt in cash at maturity, thus avoiding additional potential dilution.
Turning now to our annual guidance for fiscal 2017. We're today updating our guidance as follows, Year-over-year growth of approximately 5% for gross orders which is unchanged from our previous guidance. Revenue within the range of approximately $380 million to $390 million. This compares to our previous guidance range of $410 million to $420 million and reflects a reduction due to the delay in the issuance of China class A licenses and extended revenue conversion timing associated with distributor orders.
Our outlook for adjusted EBITDA is a range of $22 million to $26 million compared to $32 million to $38 million previously and reflects our revised revenue outlook and an operating expense decline of 8% to 10% compared to the prior year. The operating expense decline from previously issued guidance is primarily due to less incentive compensation expenses associated with the revised revenue range.
We anticipate closing out fiscal 2017 with product system backlog of approximately $445 million to $460 million. This includes Q4 age-outs of approximately $15 million to $20 million. Age-out as a percentage of ending backlog for the full year fiscal 2017 would represent a slight improvement over fiscal 2016 and ending backlog would show growth of 10% to 13% over prior year.
And with that, I would now like to hand the call back to Josh.
Joshua Levine
Thanks, Kevin. Before we open up the call for your questions, I'd like to thank the entire Accuray team for their focus and contribution this quarter. Our company's commitment to the important work we're doing in improving the lives of cancer patients by providing leading-edge treatment solutions remains central to our mission.
And now, operator, we're ready to open it up for questions.
Question-and-Answer Session
Operator
[Operator Instructions]. Our first question comes from the line of Tycho Peterson with JPMorgan.

Tycho Peterson
Josh, maybe on the distributor dynamics. I know you called this out last quarter, but you had reaffirmed guidance last quarter and kind of anticipated that this would be kind of a manageable issue. Can you maybe just talk about, to the extent that you are taking steps -- and I know you talked a little bit about this in the last earnings call in terms of trying to accelerate that conversion, maybe just talk about any incremental progress you've had there and how long do you think it takes to resolve these issues.
Joshua Levine
So I think we've made some progress, but I don't think that progress, Tyco, has been enough. It's one of the reasons why we're putting the role that we described in our prepared remarks in place and getting better focus on and better alignment. I think that -- you remember the conversation we had at the end of last quarter, this is a consequence, quite frankly, in terms of the mix -- the order mix in the backlog. It's primarily in the markets or regions where we have bigger distributor order growth taking place.
And as a consequence, we basically don't have the same clear line of sight around those basic activities that are -- we're managing on our own in the direct business, like site planning, installation planning, coordination of contractors. We have a distributor in the middle of those conversations. We have an end user that we're trying to coordinate calendarization of those activities with which creates a longer revenue conversion cycle. The strategy and the thought process around the VP of Revenue role is that we have one person there at that point that drives the forecasting process, but the details that underpin the forecasting process such as the entire end-to-end order revenue conversion process, so coordination, working with our regional installation and service teams, coordinating with the distribution partners and the end-user facilities to ensure that we've got essentially the pieces moving in the right direction to improve installation cadence and execution. And so there are some process changes that I think that will take place.
I don't see those as sweeping. But the creation of this dedicated role focused on this process from end to end, I think, will be a very, very helpful piece to improved forecast predictability. And I also think that having this position report to Kevin Waters puts added visibility and a sense of process discipline and urgency to it that, quite frankly, in my view, have been somewhat lacking. So that's the high-level thought process about the strategy with it.
Tycho Peterson
Okay. And then for my follow-up, just on competitive dynamics. Last quarter, I think you talked about winning 75% to 80% of replacement orders. Is that kind of still holding? And as we think about early interest in Onrad, how do you think about just competitive dynamics there? Obviously, Varian is talking about launching a new lower-end system for emerging markets as well.
Joshua Levine
Yes. So nothing has changed with regards to the order mix and what's impacting it. We're still seeing roughly 10% to 20% of the order mix coming from the installed base replacement opportunities. The -- that means, by definition, the remaining roughly 80% to 90% of orders are coming either from greenfield opportunities or competitive opportunities. And so as I mentioned in my prepared remarks, we -- on a global basis, we're still seeing winning at a higher rate than we're giving up our own bunkers. So we feel good about that. Radixact has been a good contributor albeit early in that discussion.
We have order activity in the third quarter that's Radixact related. And this is the first quarter of true full commercial launch. So we have basically all of our reference sites now up and running and actively treating patients which is going to help expand the sales process and the advancement in terms of sales funnel for this, in general. We've heard the market chatter about what Varian may or may not be coming to the market with an escrow. But at this point, it's too early to speculate on what that might mean or what the potential impact of that is. We've gotten really good feedback from the sites that are using Radixact in terms of tangible differences in the treatment planning capability and treatment speed. So we feel good about early functionality, early feedback on functionality at this point that Radixact has been getting.

Operator
Our next question comes from Josh Jennings with Cowen and Company.
Joshua Jennings
I was hoping to follow up on the revenue conversion issue. And can you just help us think about as we get into fiscal '18 and you anniversary the revenue conversion lag times, how does that start to play out? Clearly, you have some new people in place and you're trying to optimize the path forward. But once you anniversary the lag times, will you be able to manage that better? Or does it just continue to cause issues in terms of revenue recognition?
Kevin Waters
Josh, this is Kevin. So we're not going to comment on 2018 guidance specifically. We'll do that on our next call. But just in a general sense, our revenue growth rates going forward should more appropriately reflect the growth in our product revenue backlog and that's not what's occurring this year. And we think by making some of these process changes, we could have the future more appropriately reflect those growth rates.
I'd also use an analogy here. And if you look at a country like Japan which is 100% distributor, where we cited their increased revenue conversion process in fiscal 2016, we've been able to put a high level of focus there. And we're now seeing Japan, for example, perform significantly above plan and be a big contributor to our results. And that's the analogy I would use when I look moving forward in regards to us doing what we can do on distributor conversion.
Joshua Jennings
Great. And the growth rates in that order delta, it was the smallest gap in many quarters. You talked about one order that you thought might fall out off of that, but that you -- that went -- turned into an installation. But are there any trends that we should be thinking about in terms of that gap narrowing as we move forward here?
Kevin Waters
Yes. I don't think there's any trend. I think -- I also pointed out that age-outs are going to be higher in our fiscal fourth quarter in our prepared remarks. But to put age-outs in perspective, we've highlighted increased revenue conversion times. We've seen others in the industry talk about this phenomenon as well. And we're going to end 2017 with approximately $40 million of orders that are older than 30 months. I'd like to point out that of those $40 million that have aged out, only $10 million of those have subsequently been canceled by the end user. So while we report age-outs, I do believe that the remaining $30 million do have the potential to be future revenue and we're seeing a bit of increased age-outs in our fourth quarter due to this increase in conversion timing.
Joshua Jennings
Great. And my last question. Just on the service revenue not dramatically lower, but it trended lower in Q3 here than we've seen in numerous quarters. How should would be thinking about service revenue growth, maybe what happened in Q3 for the sequential downtick and then how we should be thinking about service revenue growth going forward?
Kevin Waters
Yes. So I'll speak to the sequential downtick. So service revenue is dependent on product revenue as well. So we record installation and training revenue at the same time as we have installs. And when we have a quarter like we did in this fiscal third quarter, where distributors in Japan, for example, perform very well, we're not responsible for installation in those markets. And therefore, we see a decline in installation and training revenue. On top of that, we also had less upgrade revenue in our fiscal third quarter. We think our service revenue growth rate should improve as we head into 2018 as we have more upgrades to offer and we can start to fill that pipeline again.
Operator
Our next question comes from Amit Hazan with Citi.
Unidentified Analyst
This is Phil [ph] on for Amit. I guess, I'll start with the other side of guidance. Maybe great order number from a gross perspective and through 3 quarters. Just what went into the decision, I guess, not to take that guidance level up for the rest of the year? Was there any pull forward that we saw or what went into that decision?

Kevin Waters
I think, just to be quite honest, given our trends and we're sitting on a call here where we've lowered revenue guidance, we're happy with our full year order guidance. However, Q4 would still suggest a number of approximately $85 million which would represent a quarterly high for us in 2017. We believe that's attainable due to the strength of our funnel, but we just didn't feel it was appropriate even though we're ahead of our expectations to look at raising that metric at the time.
With that said, as we exit 2017, our second half growth rate orders would be kind of in the 11% to 12% range. And I think that's pointing to a lot of the initiatives that Josh highlighted in terms of the full Radixact launch and some of our success in the replacement cycle. But again, we're happy to be ahead where we expect it to be. But we just thought given the Q4 absolute numbers, it's still a large number. It wouldn't be appropriate to raise that metric.
Unidentified Analyst
Right. Understood. Sounds good. Maybe just a little bit higher level, any comment on either pricing or purchasing trends maybe in light of political AHCA uncertainty? Anything you've seen there would be great.
Joshua Levine
No impact, Phil [ph], at least from an AHCA discussion standpoint. And I'd say pricing has continued to operate or flow at the levels that we expected it to. We don't see any major degradation there, so I'd say it's fairly stable.
Operator
Our next question comes from the line of Brandon Henry with RBC Capital Markets.
Brandon Henry
So you guys lowered revenue guidance by $30 million. Can you help me parse out what the impact was from the continued delay from Chinese class A quotas and then what the impact was in the longer distributor conversions?
Kevin Waters
Yes. So it's roughly equal. So the China class A delay, we were anticipating approximately $10 million to $15 million in the back half of our fiscal year and probably more in the high end there. So you're looking at a $15 million shortfall from China class A. And then it'd be a roughly equal contribution from the delay of the distributor orders that Josh discussed. That distributor conversion, by the way, I'd point out, was primarily for orders in Eastern Europe due both to construction and end-user project delays.
Brandon Henry
Okay. And then separately, you guys mentioned that ASTRO and ACRO are working on bundled payment model for radiation oncology. Can you give us a sense regarding the potential timing of implementation of these initiatives and how quickly you think they'll be rolled out?
Joshua Levine
Brandon, we don't have -- we're tracking it, but we don't have any greater insights than you do on timing. We know that the inputs to CMS have been made and CMS is expected to release a report sometime fairly soon. But don't have visibility on exact timing of that. So I guess, it's a stay tuned kind of answer. But again, our takeaway on this is that when you think about episodic payment structures and models and you think about what really is implied there with regards to the opportunity both clinically for the patient, overall experience for the patient and the payer market impact in terms of the economics -- the health economic impact of this, all signs point to the fact that hypofractionated treatment, SBRT in a hypofractionated form is really a good solution for all of those constituencies that I just talked about. And we, quite frankly, think we're really well positioned with our current portfolio to help take advantage of that. I guess, from a timing standpoint, we think this is relatively soon, maybe this summer. But again, I don't know -- we don't have an exact time frame.
Operator
Our next question comes from Christian Moore with Jefferies.
Christian Moore

Maybe one on Radixact. It seems like it's progressing well. We were just wondering if you could help quantify the contributions to the gross orders. And just by geography, a little color on what you're seeing in Radixact uptake. Obviously, it's in Japan now and how the ramp in Europe and U.S. is going as well.
Kevin Waters
Yes. This is Kevin. So we have said that roughly 50% of our orders were CyberKnife orders in Josh's remarks which means the other 50% are on the TomoTherapy platform. We're not going to break out what amount of TomoTherapy platform orders were the H Series versus Radixact. What I will say is that we did have -- Radixact was a significant contributor to that number. We did have initial placements in Japan with Shonin approval which we received in January which was above our expectations. And then we also have CE Mark for Radixact in the Eurozone and also obviously FDA approval. And so that's why continue to sell that product.
Christian Moore
And then maybe one just on the upcoming ASTRO conference. Have you factored in anything from a competitive launch standpoint in terms of what Varian is expected to be bringing into the market for fiscal '17 or beyond in your models? And is there anything else that investor -- that you want us to be paying attention to?
Joshua Levine
Yes. I mean, I think the direct answer on factoring things into forward looking, in fact, is -- when I say forward looking, I guess, I'm referring to fiscal '18. We're not going to be talking about guidance or expectations on '18 until we get to our year-end earnings release. But we -- the forecast that we're running to, from an internal standpoint, are to take into account what we know right now. And again, I think I indicated before that we have heard some market noise, customer noise about a Varian product launch in escrow, but we don't have any further information than you do beyond what was communicated yesterday in Varian's release. It sounds like it's a product that may be more focused on emerging markets. But I think that's at this point speculation on what it means. And specific impact, it's too early to really predict.
Operator
Our next question comes from the line of Sean Lavin with BTIG.
Ryan Zimmerman
This is actually Ryan on for Sean. So just one for Kevin. With the operational changes underway and the process improvements related to revenue conversion, should we be thinking about any onetime charges or nonrecurring charges over the next few quarters as you guys implement those processes?
Kevin Waters
No. In fact, all of the discussion -- changes that Josh referenced, any onetime severance thing is already factored into our operating expense guidance that we gave. I would expect that as we staff this function, there could be additional adds but nothing material. We'd still be able to adhere to kind of our operating expense run rate. So nothing unusual there.
Operator
Showing no further questions in queue at this time, I'd like to turn the call back to Mr. Levine for any closing remarks.
Joshua Levine
Thank you, operator and thank you, everyone, for your participation this afternoon. We look forward to talking with you on our fiscal fourth quarter earnings call. Thanks and have a good evening.
Operator
Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program and you may now disconnect. Everyone, have a great day. 
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!
About this article:ExpandTagged: Healthcare, Medical Appliances & Equipment, TranscriptsError in this transcript? Let us know.Contact us to add your company to our coverage or use transcripts in your business.Learn more about Seeking Alpha transcripts here.Follow SA Transcripts and get email alertsSearch TranscriptThis transcriptFindAll transcriptsFindCompare To:All ARAY TranscriptsOther Companies in this sector









Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #49bf0b20-6e9c-11e7-a53c-ada1a1516346
          





            Powered by
            PerimeterX
            , Inc.
          














Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #49e8da40-6e9c-11e7-8e50-f1790e1a0263
          





            Powered by
            PerimeterX
            , Inc.
          













Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on‚Ä¶ We‚Äôre sorry but this didn‚Äôt work.                  You can‚Äôt turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let‚Äôs get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser‚Äôs Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the ‚ÄúPersonalized ads in this browser‚Äù tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft‚Äôs privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show ‚Äúgeneric‚Äù ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show ‚Äúgeneric‚Äù ads, click Off.         If you choose ‚Äúgeneric‚Äù ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You‚Äôll still see ads, but they won‚Äôt be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
¬© 2017 Microsoft













Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          ¬© 1996-2014, Amazon.com, Inc. or its affiliates
          











Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          ¬© 1996-2014, Amazon.com, Inc. or its affiliates
          











Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          ¬© 1996-2014, Amazon.com, Inc. or its affiliates
          
















Amazon Trade-In: Get Paid for Your Used Items












 


























Interesting Finds Updated Daily










Amazon




    Try Prime
  


















Amazon Trade-In



Amazon Trade-In
All Departments





Go

















Departments









EN

¬†
      




Hello. Sign inAccount & ListsSign inAccount & ListsOrdersTry PrimeCart0






Your Amazon.comToday's DealsGift Cards & RegistrySellHelpDisability Customer Support 






Trade-In Submit Your Trade-Ins Trade-in  Customer Support
























































































         Turn in your used items for an Amazon Gift Card.
        
 



 
 
 

























            Discover the value of your items
           



 
 
 


      Add or remove suggested items from your Trade-In List that you bought from Amazon or elsewhere.
     
 













        Find more items
       
 
 
 
 
 




 



 


                Cellphones
               
 
 
 
 
 
 




 



 


                Tablets or laptops
               
 
 
 
 
 
 




 



 


                Video games or consoles
               
 
 
 
 
 
 




 



 


                Books
               
 
 
 
 
 
 
 
 





          Trade in items selected above
        

 
 
 
 








































































































































































Frequently Asked Questions








What is the Amazon Trade-In program?
The Amazon Trade-In program allows customers to receive an Amazon Gift Card in exchange for hundreds of thousands of eligible items including video games, Kindles, books, electronics, DVDs, and more. The process is easy and convenient with an immediate offer and free shipping.
How long will it take to receive payment once I trade in my item?
Depending on your location, trade-in items may take up to 10 business days to arrive before they are processed. The packages you sent can be tracked anytime in Your Trade-In Account.
Once your item is received and appraised, you'll receive an e-mail notification within 2 business days informing you whether your items were accepted or rejected. You can find the status of your trade-in anytime in Your Trade-In Account. Once your trade-in value has been paid, you'll see the amount when viewing your gift card balance.
Qualified customers can also choose to be paid immediately when submitting a video game, console, or accessory trade-in by selecting the Instant Payment option.
What condition do my items need to be in?
In general, all items you wish to trade in must match the exact version displayed in the Trade-In search results or on the product page on Amazon.com. You can find the full condition descriptions by visiting our Product Eligibility Criteria page.
Are there any shipping or other fees?
When submitting a trade-in, customers will print a free pre-paid shipping label for sending in all items. There are no fees. If a trade-in item is not accepted and is returned, there is no cost for return shipping.
What do I do if I lost my shipping label?
You can print a shipping label at any time by going to Your Trade-In Account and clicking the Print Shipping Label button on the trade-in order.
If you have multiple packages or other shipping questions, check out our Packing and Shipping Instructions.
Can I use the Amazon App to trade in my items?
Yes, you can use the Amazon App on both Android and iOS phones to trade in. Simply open the app and scan or search for your items. Trade-In eligible items will have a Trade-In button on the product pages.
Can I trade in an item that isn't listed in the Trade-In Store?
If your item is not listed in the Trade-In Store, then we currently do not have an offer for it. However the Trade-In program is constantly updated with new items, so check back regularly.
How long do I have to ship my items?
Please make sure your trade-in is postmarked within 7 calendar days of submission and the item meets or exceeds the product eligibility criteria in order to receive the trade-in value listed on the website.
Who do I contact with questions about my trade-in?
The most recent status of your trade-in is available online anytime in Your Trade-In Account.
If you need help submitting the items you want to trade in, you can contact Amazon Customer Service via phone, chat, or e-mail by clicking the Contact Us button on any Help page.
You can find full program details by visiting our Amazon Trade-In Program Terms & Conditions page.


































        Your recently viewed items and featured recommendations
    



 ‚Ä∫ 
View or edit your browsing history

After viewing product detail pages, look here to find an easy way to navigate back to pages you are interested in.






        Your recently viewed items and featured recommendations
    



 ‚Ä∫ 
View or edit your browsing history

After viewing product detail pages, look here to find an easy way to navigate back to pages you are interested in.













There's a problem loading this menu right now.
Learn more about Amazon Prime.






 Get fast, free shipping with Amazon Prime 
 Prime members enjoy FREE Two-Day Shipping and exclusive access to music, movies, TV shows, original audio series, and Kindle books. 

      >
      Get started















Back to top
Get to Know UsCareersAbout AmazonInvestor RelationsAmazon DevicesMake Money with UsSell on AmazonSell Your Services on AmazonSell on Amazon BusinessSell Your Apps on AmazonBecome an AffiliateAdvertise Your ProductsSelf-Publish with UsBecome an Amazon VendorSell Your Subscription on Amazon‚Ä∫See allAmazon Payment ProductsAmazon Rewards Visa Signature CardsAmazon.com Store CardAmazon.com Corporate Credit LineShop with PointsCredit Card MarketplaceReload Your BalanceAmazon Currency ConverterLet Us Help YouYour AccountYour OrdersShipping Rates & PoliciesAmazon PrimeReturns & ReplacementsManage Your Content and DevicesAmazon AssistantHelp




English



United States




Amazon Music Stream millions of songs

Amazon Drive Cloud storage from Amazon

6pm Score deals on fashion brands

AbeBooks Books, art & collectibles

ACX  Audiobook Publishing Made Easy

Alexa Actionable Analytics for the Web

Amazon Business Everything For Your Business

¬†

AmazonFresh Groceries & More Right To Your Door

AmazonGlobal Ship Orders Internationally

Home Services Handpicked Pros Happiness Guarantee

Amazon Inspire Digital Educational  Resources

Amazon Rapids Fun stories for  kids on the go

Amazon Restaurants Food delivery from local restaurants

Amazon Video Direct Video Distribution Made Easy

¬†

Amazon Web Services Scalable Cloud Computing Services

Audible Download Audio Books

AudiobookStand Discount Audiobooks on Disc

Book Depository Books With Free Delivery Worldwide

Box Office Mojo Find Movie Box Office Data

ComiXology Thousands of Digital Comics

CreateSpace Indie Print Publishing Made Easy

¬†

DPReview Digital Photography

East Dane Designer Men's Fashion

Fabric Sewing, Quilting & Knitting

Goodreads Book reviews & recommendations

IMDb Movies, TV & Celebrities

IMDbPro Get Info Entertainment Professionals Need

Junglee.com Shop Online in India

¬†

Kindle Direct Publishing Indie Digital Publishing Made Easy


Prime Now FREE 2-Hour Delivery on Everyday Items

Prime Photos Unlimited Photo Storage Free With Prime

Shopbop Designer Fashion Brands

TenMarks.com Math Activities for Kids & Schools

Warehouse Deals Open-Box Discounts

Whispercast Discover & Distribute Digital Content


¬†

¬†

Withoutabox Submit to Film Festivals

Woot! Deals and  Shenanigans

Zappos Shoes & Clothing

Souq.com Shop Online in the Middle East

Subscribe with Amazon Discover & try subscription services

¬†


Conditions of UsePrivacy NoticeInterest-Based Ads¬© 1996-2017, Amazon.com, Inc. or its affiliates














Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...



First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





This is me
Searching for yourself?




Search





  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate‚Ä¶ Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip






















Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...



First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





This is me
Searching for yourself?




Search





  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate‚Ä¶ Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip






















Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...



First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





This is me
Searching for yourself?




Search





  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate‚Ä¶ Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip






















Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...



First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





This is me
Searching for yourself?




Search





  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate‚Ä¶ Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip






















Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...




First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





we also search social networks:

















This is me
Searching for yourself?




Search






  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate‚Ä¶ Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip
















